

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Effects of Removing Restriction of Reimbursement for Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022293
Article Type:	Research
Date Submitted by the Author:	21-Feb-2018
Complete List of Authors:	Hsu, Jason C.; National Cheng Kung University, School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine Wei, Chen-Fang ; National Taiwan University Hospital Hsin-Chu Branch, Department of Pharmacy Yang, Szu-Chun ; National Cheng Kung University Hospital, Department of Internal Medicine
Keywords:	Targeted therapies, Lung cancer, Reimbursement policy, Interrupted time series

SCHOLARONE™
Manuscripts

Peer Review Only

Title Page

Effects of Removing Restriction of Reimbursement for Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Jason C. Hsu¹; Chen-Fang Wei²; Szu-Chun Yang³

1. School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan; 2. Department of Pharmacy, National Taiwan University Hospital Hsin-Chu Branch, Taiwan; 3. Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan

Corresponding author:

Jason C. Hsu, Ph.D.

Email address: jasonhsu@harvard@gmail.com

Postal Address: No.1, Daxue Rd., East Dist., Tainan City 70101, Taiwan (R.O.C.)

Phone: 1-886-985518678

Abstract

Interventions: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib, a targeted therapy, was initially approved and reimbursed as third-line therapy for advanced NSCLC patients by Taiwan National Health Insurance in 2004; subsequently they became second-line (in 2007) and further first-line (in 2011) therapies for EGFR mutation-positive, advanced NSCLC patients. Another targeted therapy, erlotinib, was initially approved as third-line therapy in 2007, and it became second-line in 2008.

Objectives: This study aims to explore the impacts of above reimbursement policies (removing restriction of reimbursement) on accessibility of targeted therapies.

Design:

1
2
3 **Setting:** We retrieved 2004-2013 claims data with all patients with lung cancer diagnosis
4 from National Health Insurance Research Database.
5

6
7 **Design and Outcome Measures:** Using an interrupted time series design and segmented
8 regression, we estimated changes in monthly rate of prescribing rate by patient number and
9 market shares by costs following each modification in the reimbursement policy for gefitinib
10 and erlotinib for NSCLC treatment.
11

12
13 **Results:** Prescribing rate of targeted therapies relatively increased by 15.58%, decreased by
14 10.98% and increased by 6.31% at three months following gefitinib as the second line
15 treatment in 2007, erlotinib as the second line treatment in 2008 and gefitinib as the first line
16 treatment in 2011 respectively. Average time to targeted therapies' prescription reduced by
17 65.84% and 41.59% at 2 years following erlotinib covered by insurance and
18 gefitinib/erlotinib as the second line treatments in 2007-2008 and following gefitinib as the
19 first line treatment in 2011 respectively.
20

21
22 **Conclusions:** The changes of the reimbursement policies had the significant impacts on the
23 utilization and accessibility of oral targeted therapies for NSCLC treatment. Removing
24 restriction of reimbursement for specific drug would increase its own use but might decrease
25 another drug's use. These interventions also significantly accelerated the prescription of
26 targeted therapies.
27

28
29
30
31
32
33
34
35
36
37
38
39
40 **Keywords:** *Lung cancer; Targeted therapies; Reimbursement policy; Interrupted time series*
41
42
43

44 **Strengths and limitations of this study**

- 45 ■ Interrupted time series design and segmented regression were applied.
- 46 ■ Removing restriction of reimbursement had significant impact on drug accessibility.
- 47 ■ Prescribing rate of targeted therapies relatively increased following the policy change.
- 48 ■ Average time to targeted therapies' prescription reduced following the policy change.
- 49 ■ Further studies about how such policies affect the clinical outcomes of treatments and
50 the cost-effectiveness of the policies are needed in the future.
51
52
53
54
55
56
57
58
59
60

Manuscript

Effects of Removing Restriction of Reimbursement for Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Abstract

Interventions: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib, a targeted therapy, was initially approved and reimbursed as third-line therapy for advanced NSCLC patients by Taiwan National Health Insurance in 2004; subsequently they became second-line (in 2007) and further first-line (in 2011) therapies for EGFR mutation-positive, advanced NSCLC patients. Another targeted therapy, erlotinib, was initially approved as third-line therapy in 2007, and it became second-line in 2008.

Objectives: This study aims to explore the impacts of above reimbursement policies (removing restriction of reimbursement) on accessibility of targeted therapies.

Design:

Setting: We retrieved 2004-2013 claims data with all patients with lung cancer diagnosis from National Health Insurance Research Database.

Design and Outcome Measures: Using an interrupted time series design and segmented regression, we estimated changes in monthly rate of prescribing rate by patient number and market shares by costs following each modification in the reimbursement policy for gefitinib and erlotinib for NSCLC treatment.

Results: Prescribing rate of targeted therapies relatively increased by 15.58%, decreased by 10.98% and increased by 6.31% at three months following gefitinib as the second line treatment in 2007, erlotinib as the second line treatment in 2008 and gefitinib as the first line treatment in 2011 respectively. Average time to targeted therapies' prescription reduced by 65.84% and 41.59% at 2 years following erlotinib covered by insurance and gefitinib/erlotinib as the second line treatments in 2007-2008 and following gefitinib as the

1
2
3 first line treatment in 2011 respectively.
4

5 **Conclusions:** The changes of the reimbursement policies had the significant impacts on the
6 utilization and accessibility of oral targeted therapies for NSCLC treatment. Removing
7 restriction of reimbursement for specific drug would increase its own use but might decrease
8 another drug's use. These interventions also significantly accelerated the prescription of
9 targeted therapies.
10
11
12
13
14

15 16 17 **Introduction**

18 Lung cancer is the leading cause of cancer deaths worldwide.¹ In the United States, in
19 2011, approximately 221,130 new cases of lung cancer (14% of all cancer diagnoses) were
20 predicted, out of which 156,940 deaths (27% of cancer deaths) were estimated to have been
21 due to lung cancer.² In Taiwan, lung cancer is also one of the most commonly diagnosed
22 cancers as well as the leading cause of cancer deaths. Approximately 11,692 new cases of
23 lung cancer (12% of all cancer diagnoses) and 8,587 deaths (20% of cancer death) were
24 expected to occur in Taiwan in 2012.³ About 85% of all lung cancers are identified as
25 non-small cell, and approximately 75% of these are metastatic or advanced at diagnosis, for
26 which no curative treatment is available.⁴⁻⁷
27
28
29
30
31
32
33
34
35

36 Since 2004, oral targeted therapies for non-small cell lung cancer have been launched
37 into the market for epidermal growth factor receptor (EGFR) mutation patients. The EGFR
38 molecular targeted drugs (MTD), gefitinib and erlotinib, were firstly approved as third-line or
39 second-line therapy for advanced NSCLC patients because of their therapeutic benefits, as
40 suggested by randomized clinical trials.⁸⁻¹⁰ The recent National Comprehensive Cancer
41 Network guideline¹¹ further suggests MTD as first-line therapy for EGFR mutation-positive,
42 advanced NSCLC patients based on cumulating evidence showing a significant association
43 between mutated EGFR and the clinical benefits of MTD.¹²⁻¹⁴ In the light of rapid disease
44 progression, access to pharmaceutical innovations such as MTD on a timely basis is vital to
45 NSCLC patients with the right indications who need it.
46
47
48
49
50
51
52
53
54

55 According to "Directions for Drug Restricted Benefits for National Health Insurance,"
56
57

1
2
3 two targeted therapies, gefitinib and erlotinib, for treatment of lung cancer have been
4 reimbursed in Taiwan since 2004 and 2007, respectively. In the beginning, both were
5 restricted for use as a third-line treatment. Gefitinib could be used as second-line therapy for
6 advanced NSCLC patients after November 2007 and has been further allowed to be used as a
7 first-line therapy for EGFR mutation-positive advanced NSCLC patients since June 2011;
8 erlotinib has been permitted for use as a second-line therapy for advanced NSCLC patients
9 since June 2008 and has been further allowed to be used as a first-line therapy for EGFR
10 mutation-positive advanced NSCLC patients since June 2013.

11
12 Little is known about the impacts of changes in targeted therapy-related reimbursement
13 policies (related to removing restriction of reimbursement and broadening eligible patient
14 population) in Taiwan. The aim of our longitudinal analyses was to address this gap by
15 examining the recent trends in utilization and expenditures of targeted therapies (gefitinib and
16 erlotinib) following changes in the reimbursement policy, which involve the accessibility and
17 economic burden of drugs. Furthermore, we also evaluated the changes of time to prescription
18 of NSCLC over time.

32 33 34 **Method**

35 36 *Data sources*

37
38 All monthly claims data, including details of prescription and insurer spending, for
39 antineoplastic agents between 2004 and 2013 were retrieved from Taiwan's National Health
40 Insurance Research Database. The database contains information from a nationwide,
41 mandatory-enrollment, single-payer healthcare system created in 1995. Nearly 99% of the
42 Taiwanese population (around 23 million residents) is enrolled, and this system contracts with
43 97% of hospitals and clinics throughout the country. The National Health Insurance (NHI)
44 covers a wide range of prescription medicines as well as inpatient and outpatient medical
45 services.¹⁵ NSCLC-related prescriptions were identified using the International Classification
46 of Diseases, 9th edition (ICD-9) diagnosis codes for cancer (codes: 162). Patients with small
47 cell lung cancer were not included in this study, and patients who had used etoposide and
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 topotecan were excluded.
4
5

6 7 ***Drugs of interest*** 8

9 We used the Anatomical Therapeutic Chemical (ATC) classification system from the
10 World Health Organization. We identified all antineoplastic agents using the ATC code “L01”.
11 Targeted therapies included in the analysis were monoclonal antibodies and protein kinase
12 inhibitors (gefitinib and erlotinib). New targeted therapies (afatinib, crizotinib, and ceritinib)
13 were not included in this study because they were not reimbursed by NHI before 2013.
14
15
16
17
18
19

20 21 ***Measurements*** 22

23 To examine the trends in the accessibility of the targeted therapies (gefitinib and
24 erlotinib) following the changes in reimbursement policies, we calculated the monthly
25 number of patients who used each targeted therapy and the related costs from 2004 to 2013.
26 Then, we estimated the proportion of their use by patient number and the market share by
27 cost among total patient numbers and total costs of all antineoplastic agents. The prescribing
28 rate of the targeted therapies by patient number was estimated by using the number of
29 patients who had used the targeted therapies divided by the number of patients who had used
30 antineoplastic agents; the market share of targeted therapies by cost was estimated by using
31 the cost of the targeted therapies divided by the cost of antineoplastic agents. The cost was
32 adjusted using the yearly consumer price index (CPI).¹⁶
33
34
35
36
37
38
39
40
41
42
43

44 45 ***Statistical Analysis*** 46

47 The Interrupted Time Series design¹⁷, a strong quasi-experimental method, was adopted
48 to evaluate the overall changes in drug utilization (prescribing rate and market share of cost)
49 before and after the four modifications to the drug reimbursement policy: (1) erlotinib was
50 covered by NHI in June 2007; (2) gefitinib became available as a second-line treatment in
51 November 2007; (3) erlotinib became available as a second-line treatment in June 2008, and
52 (4) gefitinib became available for first-line treatment in June 2011. For average time to
53
54
55
56
57

1
2
3 prescription, we combined the previous three policy changes as one intervention due to the
4 fact that their timing was similar. A segmented linear regression model was used to estimate
5 post-policy changes in both the level and trend of these study outcomes.¹⁸⁻²¹ Using baseline
6 trends, we projected rates over time with the assumption that the baseline trend reflected what
7 would have happened without the implementation of the promotion strategies. The basic
8 model included terms to estimate the baseline level for each outcome (intercept), baseline
9 trend (slope), changes in the level immediately after policy implementation, and changes in
10 the trend after the policy change.^{17,22} Our models also controlled for autocorrelation.²³ To
11 identify the most parsimonious models, we used backward elimination and excluded
12 non-significant terms ($P>0.05$). To summarize the results as a single metric, we estimated
13 absolute and relative changes (with 95% confidence intervals, CI)²⁴ in outcomes 3 months
14 following the interventions compared to projected rates. All analyses were carried out with
15 SAS software, Version 9.4 (SAS Institute, Cary, NC).
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 ***Patient and Public Involvement***

31 Patients were not involved in this study.
32
33
34
35

36 **Results**

37 ***Prescribing rate of targeted therapies by patient number***

38
39
40 Table 1 presents the prescribing rate by patient number and the market share by cost of
41 the targeted therapies over time. Overall, the number of patients who had used the targeted
42 therapies (gefitinib and erlotinib) increased from 228 in 2004 to 8,542 in 2013, which
43 accounted for 5.48% of patients who had used antineoplastic agents in 2004 and 58.52% who
44 had used them in 2013. Among these, the number of patients who had used gefitinib
45 increased from 228 (5.48% of patients who used antineoplastic agents) in 2004 to 5,558
46 (38.08%) in 2013; the number of patients who had used erlotinib increased from 499 (8.44%)
47 in 2007 to 2,984 (20.44%) in 2013.
48
49
50
51
52
53
54
55
56
57
58
59
60

[Table 1]

Market share of targeted therapies by costs

During the 10-year study period, the estimated market share of targeted therapies by costs increased from US\$573,515 in 2004 to US\$57,165,899 in 2013, which accounted for 3.85% in 2004 and 62.38% in 2013 of the cost of antineoplastic agents. Among these, the cost of gefitinib increased from US\$573,515 (3.85% of cost of antineoplastic agents) in 2004 to US\$41,677,315 (45.48%) in 2013; the cost of erlotinib increased from US\$2,694,918 (9.13%) in 2007 to US\$15,488,583 (16.9%) in 2013.

Effects of multiple changes in reimbursement policies on the use of targeted therapies

Targeted therapies

The prescribing rate of targeted therapies remained steady after erlotinib was covered by NHI in June 2007 (Table 2). There was a relative increase of 15.58% in the prescribing rate of the targeted therapies 3 months after gefitinib became available as a second-line treatment in November 2007, while there was a relative reduction of 10.98% after erlotinib became available as a second-line treatment in June 2008. After gefitinib became available as a first line-treatment in June 2011, it rose relatively by 6.31%. Figure 1 (A) shows the prescribing rate of the targeted therapies by patient number over time.

The market share of targeted therapies by cost remained steady after erlotinib was covered by NHI in June 2007. Gefitinib became available as a second-line treatment in November 2007 and became available as a first line-treatment in June 2011. There was a relative decline of 4.33% in the market share of the targeted therapies by costs 3 months after erlotinib became available as a second- line treatment in June 2008.

[Table 2] [Figure 1]

Gefitinib

The prescribing rate of gefitinib decreased by 20.69% after erlotinib was covered by NHI in June 2007. It increased by 54.32%, decreased by 13.27%, and increased by 21.76% after gefitinib became available as a second-line treatment in November 2007; erlotinib became available as a second-line treatment in June 2008, and gefitinib became available as a first-line treatment in June 2011, respectively. Figure 1 (B) shows the prescribing rate of gefitinib by patient number over time.

There was a relative reduction of 6.59% in market share by cost for gefitinib after erlotinib was covered by NHI in June 2007. This did not change after gefitinib became available as a second-line treatment in November 2007, and erlotinib became a second-line treatment in June 2008. However, the market share by cost increased by 16.63% after gefitinib became available as a first-line treatment in June 2011.

Erlotinib

The prescribing rate of erlotinib declined relatively by 26.79% after gefitinib became available as a second line treatment in November 2007. It increased by 22.62% and decreased by 10.3% after erlotinib became available as a second line treatment in June 2008, and gefitinib became available as a first line treatment in June 2011, respectively. Figure 1 (C) shows the prescribing rate of erlotinib by patient number over time.

There was a relative reduction of 30.33% in market share by cost for erlotinib after gefitinib became available as a second line treatment in November 2007. It increased by 21.66% and decreased by 9.3% after erlotinib became available as a second line treatment in June 2008, and gefitinib became available as a first line treatment in June 2011, respectively.

Time to prescriptions of the targeted therapies

The average time to prescription of the targeted therapies are shown in Table 3, and the estimated changes in time to prescription following changes in the reimbursement policies are presented in Table 4. The average time to prescription of the targeted therapies rapidly

1
2
3 decreased from 802 days (S.D.=654.6) in 2004 to 43 days (S.D.=49.6) in 2013 (Table 3). It
4 reduced by 65.84% after erlotinib was covered by the NHI, and gefitinib/erlotinib became
5 available as second line treatments in 2007 and 2008 and further decreased by 41.59% after
6 gefitinib became available as a first line treatment in 2011 (Table 4). The average time to
7 prescription of gefitinib decreased from 685 days (S.D.=587.4) in 2004 to 33 days (S.D.=33.7)
8 in 2013 (Table 3). There was a relative growth of 39.82% in time to prescription for gefitinib
9 after erlotinib was covered by NHI, and gefitinib/erlotinib became available as second line
10 treatments, while there was a relative decline of 69.57% after gefitinib became a first line
11 treatment (Table 4). The average time to prescription of erlotinib decreased from 1,602 days
12 (S.D.=520.7) in 2004 to 129 days (S.D.=70.8) in 2013 (Table 3). It dropped substantially by
13 234.37% after erlotinib was covered by the NHI, and gefitinib/erlotinib became available as
14 second line treatments, but it did not change after gefitinib became available as a first line
15 treatment (Table 4).
16
17
18
19
20
21
22
23
24
25
26
27

28 [Table 3] [Table 4]
29
30
31

32 Discussion

33
34
35

36 In this study, the large NHIRD database was taken advantage of to examine 2004-2013
37 (10 years) of the use of targeted therapies for NSCLC lung cancer. Using a strong
38 quantitative research method (interrupted time series), our findings revealed changes in the
39 accessibility of the targeted therapies, including the prescribing rate, prescription speed, and
40 economic burden, following a series of reimbursement policy modifications.
41
42
43
44
45

46 It was found that four interventions had significant and diverse effects on gefitinib and
47 erlotinib use. To understand the impacts of the drug reimbursement policy of “removing
48 restriction of reimbursement and broadening eligible patient population”, the prescribing rate
49 and prescription speed were used to represent the accessibility of drugs. The results made it
50 possible to determine whether “removing restriction of reimbursement and broadening
51 eligible patient population” actually allowed more patients to have access to the targeted
52
53
54
55
56
57
58
59
60

1
2
3 therapies.

4
5 In the case of gefitinib, the prescribing rate has steadily risen since it was first covered
6 by NHI in 2004. Then, the coverage of erlotinib (as a third line) for NSCLC resulted in a drop
7 in gefitinib by 20% (prescribing rate) and 6% (market share by expenditure). A few months
8 later, when gefitinib became available as a second line treatment, this caused the greatest
9 changes in gefitinib use (54.32% reduction). When erlotinib became available as a
10 second-line treatment, gefitinib's use reduced by 13%. Then, gefitinib's prescribing rates and
11 expenditures rose again (21% increase in prescribing rate, 17% in expenditures) when
12 gefitinib became available as a first line treatment.

13
14 In the case of erlotinib, three changes in the reimbursement rules had significant effects
15 on prescribing rates and market share by cost. Especially, after gefitinib became available as a
16 second line treatment, the prescribing rate and market share of cost decreased by 27% and
17 30%, respectively. In addition, the previous rates of erlotinib reduced by 10% and 9%,
18 respectively, after gefitinib became available as a first line treatment. On the other hand,
19 when erlotinib became available as a second line treatment, approximately 23% and 22%
20 increases in prescribing rates and market share by costs were observed, respectively.

21
22 The overall use of oral targeted therapies (gefitinib and erlotinib) did not rise following
23 the introduction of erlotinib in June 2007. However, use significantly rose by 15% when
24 gefitinib became available as a second-line treatment in November 2007, while it fell by 10%
25 when erlotinib became available as a second-line treatment in June 2008. When gefitinib
26 became available as a first-line treatment, the overall prescription ratio of oral targeted
27 therapies only increased by 6%. On the other hand, the market share of cost of oral targeted
28 therapies was only slightly diminished when erlotinib became available as a second-line
29 treatment in June 2008, but it was not affected by other interventions. In general, these
30 changes in the reimbursement rules were effective with regard to improving the accessibility
31 of the targeted therapies.

32
33 As far as the speed of accessibility of the targeted therapies related to NSCLC treatment,
34 average time to prescription for targeted therapies gradually reduced from 802 days in 2004
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

1
2
3 to 43 days in 2013. This means the changes in the reimbursement rules (removing restriction
4 of reimbursement and broadening eligible patient population) markedly accelerated the
5 accessibility of targeted therapies.
6
7

8
9 This study had several limitations. First, the study focused on the effects of removing
10 restriction of reimbursement and broadening eligible patient population related to the
11 accessibility of medicines. We used three indicators: prescribing rate, market share of cost,
12 and time to prescription, as measurements of accessibility of medicine. Due to the lack of
13 clinical test data in the Taiwan NHIRD claims database, this study was not able to identify
14 patients' eligibility to obtain the targeted therapies based on clinical testing (such as
15 pathology or cytological results, and EGFR-TK gene mutation test results, etc.). Secondly,
16 this study analyzed data from the Taiwan NHIRD claims database that did not cover data for
17 payments made by patients themselves. Hence, there may be differences between the
18 estimated prescription rate / costs and the actual value. However, this gap is not believed to
19 be very significant since the proportion of payments made by patients themselves was very
20 small. Third, considering the timing of drug launches, during the study period (2004-2013),
21 only two targeted therapies (gefitinib and erlotinib) could be included, and newer medicines
22 were out of the scope of this study. Finally, this study was aimed toward an examination of
23 the effects of removing restriction of reimbursement and broadening eligible patient
24 population related to accessibility to the targeted therapies. Further studies about how such
25 policies affect the clinical outcomes of treatments and the cost-effectiveness of the policies
26 are needed in the future.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Conclusion**

47
48 The present study examined how multiple reimbursement policies have changed
49 accessibility, utilization, and clinical outcomes of targeted therapies. Overall, removing
50 restriction of reimbursement and broadening eligible patient population for NSCLC targeted
51 therapies improved the accessibility of such medications. In detail, when a targeted therapy
52 became available for either early or broad use, it increased in terms of utilization but in turn
53
54
55
56
57
58
59
60

1
2
3 may have decreased the use of other drugs in a similar class. In addition, the targeted
4 therapies were prescribed earlier once their insurance reimbursement restrictions were lifted.
5
6 The results of this study can be used as the empirical basis for clinical treatment, to help
7 enhance the content of academic literature on this subject, and can serve as the empirical
8
9 basis for future targeted therapy studies.
10
11
12
13

14 ■ **Author Contributions**

15 JCH and SCY conceptualized and designed the study. CFW collected data, performed
16 analysis, and drafted the manuscript. JCH and SCY reviewed all data and revised the
17 manuscript critically for intellectual content. All authors approved the final version for
18 submission.
19
20
21

22 ■ **Competing Interests**

23 The authors have no competing interests.
24
25

26 ■ **Funding**

27 Dr. Hsu was supported by Taiwan Ministry of Science and Technology grants (Grant ID:
28 MOST 104-2320-B-006-005, MOST 106-2320-B-006-039). The funders had no role in study
29 design, data collection and analysis, decision to publish, or preparation of the manuscript.
30
31
32

33 ■ **Data Sharing Statement**

34 The authors have obtained nationwide, monthly claims data for NSCLC patients, from 2004
35 to 2013, from the Taiwan National Health Insurance Research Database (NHIRD). NHIRD
36 does not permit external sharing of any of the data elements. No additional data available.
37
38
39

40 **References**

- 41 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide
42 burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893-917.
43
- 44 2. American Cancer Society: Cancer Facts & Figures 2012. Atlanta: American Cancer
45 Society. 2012.
- 46 3. Cancer Registry Annual Report, 2011, Taiwan. Health Promotion Administration,
47 Ministry of Health and Welfare 2014.
- 48 4. Pfizer Oncology, Lung cancer fact sheet. 2012.
- 49 5. Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential
50
51
52
53
54
55
56
57

- 1
2
3 role of cetuximab. *Biologics* 2009;3:215-24.
4
5 6. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer
6
7 therapy. *Expert Rev Anticancer Ther* 2007;7:1423-37.
8
9 7. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus
10
11 irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus
12
13 vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
14
15 *Ann Oncol* 2007;18:317-23.
16
17 8. Chen HL, Shen LJ, Wei CP, Lu HM, Hsiao FY. Decision to adopt medical technology
18
19 under the National Health Insurance System in Taiwan: case study of new molecular targeted
20
21 drugs among non-small cell lung cancer patients. *J Eval Clin Pract* 2015;21:808-16.
22
23 9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated
24
25 non-small-cell lung cancer. *N Engl J Med* 2005;353:123-32.
26
27 10. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of
28
29 non-small-cell lung cancer with erlotinib or gefitinib. *N Engl J Med* 2011;364:947-55.
30
31 11. NCCN Clinical Practice Guidelines in Oncology (2013) Non-Small Cell Lung Cancer, p.
32
33 2. National Comprehensive Cancer Network. Available at: <http://www.nccn.org/index.asp>
34
35 [accessed on Dec. 19,2015].
36
37 12. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for
38
39 non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8.
40
41 13. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. *Jpn J*
42
43 *Clin Oncol* 2009;39:137-50.
44
45 14. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary
46
47 adenocarcinoma. *N Engl J Med* 2009;361:947-57.
48
49 15. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug
50
51 copayment policy in the elderly. *Med Care* 2003;41:1331-42.
52
53 16. Analytic Hierarchy Process: Theory and Practice. 2009. (Accessed December 15, 2017,
54
55 at ftp://mail.im.tku.edu.tw/Prof_Shyur/AHP/AHP2009.pdf.)
56
57 17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of

1
2
3 interrupted time series studies in medication use research. *J Clin Pharm Ther*
4 2002;27:299-309.

5
6
7 18. Lu CY, Ross-Degnan D, Stephens P, Liu B, Wagner AK. Changes in use of antidiabetic
8 medications following price regulations in China (1999–2009). *Journal of Pharmaceutical*
9 *Health Services Research* 2013;4:3-11.

10
11
12 19. Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and
13 suicidal behavior after FDA warnings and media coverage: quasi-experimental study. *BMJ*
14 2014;348:g3596.

15
16
17 20. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug
18 reimbursement reductions on utilization and expenditures of oral antidiabetic medications in
19 Taiwan: an interrupted time series study. *Health Policy* 2014;116:196-205.

20
21
22 21. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a
23 Medicaid prior authorization policy on access to medications for bipolar illness. *Med Care*
24 2010;48:4-9.

25
26
27 22. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the
28 management and outcomes of hypertension in the United Kingdom: interrupted time series
29 study. *BMJ* 2011;342:d108.

30
31
32 23. Shadish WC, T.; Campbell, D. *Experimental and Quasi-experimental Designs for*
33 *Generalized Causal Inference* Houghton Mifflin 2002.

34
35
36 24. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating
37 confidence intervals in interrupted time series analyses of health interventions. *J Clin*
38 *Epidemiol* 2009;62:143-8.

Table 1. Prescription rate by patient number and market share by costs of targeted therapies over time (2004-2013)

	Prescription rate by patient number						Market share by costs							
	Number of patients who used antineoplastic agents	Number of patients who used gefitinib	(%)	Number of patients who used erlotinib	(%)	Number of patient who used targeted therapies (gefitinib + erlotinib)	(%)	Cost of antineoplastic agents (US\$)	Cost of gefitinib (US\$)	(%)	Cost of erlotinib (US\$)	(%)	Cost of Targeted therapies (gefitinib + erlotinib) (US\$)	(%)
2004	4,162	228	5.48	0	0.00	228	5.48	14,887,913	573,515	3.85	0	0.00	573,515	3.85
2005	4,876	872	17.88	0	0.00	872	17.88	22,446,991	8,015,889	35.71	0	0.00	8,015,889	35.71
2006	5,173	1095	21.17	0	0.00	1095	21.17	27,126,263	10,435,769	38.47	0	0.00	10,435,769	38.47
2007	5,909	1413	23.91	499	8.44	1912	32.36	29,531,282	12,265,156	41.53	2,694,918	9.13	14,960,074	50.66
2008	7,130	1975	27.70	1418	19.89	3393	47.59	43,162,957	18,784,869	43.52	11,190,711	25.93	29,975,581	69.45
2009	7,673	1922	25.05	2090	27.24	4012	52.29	48,988,605	17,276,102	35.27	18,099,806	36.95	35,375,908	72.21
2010	8,200	2058	25.10	2445	29.82	4503	54.91	51,384,668	16,242,224	31.61	20,207,860	39.33	36,450,084	70.94
2011	10,254	3440	33.55	2754	26.86	6194	60.41	58,115,193	20,942,858	36.04	19,298,723	33.21	40,241,581	69.24
2012	12,621	5011	39.70	3029	24.00	8040	63.70	76,127,283	36,628,520	48.11	17,785,455	23.36	54,413,975	71.48
2013	14,597	5558	38.08	2984	20.44	8542	58.52	91,642,044	41,677,315	45.48	15,488,583	16.90	57,165,899	62.38

Table 2. Estimated changes in targeted therapies utilization following changes in reimbursement policies using segmented regression models

Changes of Drug Utilization																			
		Effects of intervention (1) erlotinib covered by NHI (third line) [200706]					Effects of intervention (2) gefitinib as second line treatment [200711]					Effects of intervention (3) erlotinib as second line treatment [200806]				Effects of intervention (4) gefitinib as first line treatment [201106]			
		Absolute		Relative			Absolute		Relative			Absolute		Relative		Absolute		Relative	
	Intercept	Baseline trend	Level change	Trend change	change (3 months later)	change (3 months later)	Level change	Trend change	change (3 months later)	change (3 months later)	Level change	Trend change	change (3 months later)	change (3 months later)	Level change	Trend change	change (3 months later)	change (3 months later)	
Prescribing rate of targeted therapies	0.0342	(0.0021, 0.0060)	--	--	--	--	--	(0.0027, 0.0215)	3.63%	15.58%	--	(-0.0226, -0.0054)	-4.20%	-10.98%	(0.0037, 0.0491)	--	2.64%	6.31%	
Prescribing rate of gefitinib	0.0263	(0.0017, 0.0067)	--	(-0.0268, -0.0024)	-4.38%	-20.69%	--	(0.0048, 0.0372)	6.3%	54.32%	--	(-0.0211, -0.0013)	-3.36%	-13.27%	(0.0026, 0.0404)	(0.0032, 0.0113)	4.32%	21.76%	
Prescribing rate of erlotinib	0.0099	(0.0059, 0.0195)	NA	NA	NA	NA	--	(-0.0173, -0.0026)	-2.99%	-26.79%	0.0228	(0.0060, 0.0396)	--	2.28%	22.62%	--	(-0.0105, -0.0048)	-2.29%	-10.30%
Market share by cost for targeted therapies	0.0446	(0.0045, 0.0091)	--	--	--	--	--	--	--	--	--	(-0.0095, -0.0028)	-1.85%	-4.33%	--	--	--	--	
Market share by cost for gefitinib	0.1030	(0.0014, 0.0072)	--	(-0.0106, -0.0023)	-1.93%	-6.59%	--	--	--	--	--	--	--	--	--	(0.0052, 0.0137)	2.85%	16.63%	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		0.0202																	
Market share by																			
cost for erlotinib	0.0194	(0.0113,	NA	NA	NA	NA	--	(-0.0278,	-5.49%	-30.33%	(0.0077,	--	3.02%	21.66%	--	(-0.0108,	-2.21%	-9.30%	
		0.0291)						-0.0088)			0.0527)					-0.0040)			

For peer review only

Table 3. Time to prescription of targeted therapies for non-small cell lung cancer treatment over time (2004-2013)

	Time to Prescription (days)					
	Targeted therapies (gefitinib + erlotinib)		Gefitinib		Erlotinib	
	Mean	S.D.	Mean	S.D.	Mean	S.D.
2004	801.7	654.6	685.3	587.4	1,602.0	520.7
2005	683.4	546.2	570.0	497.4	1,128.7	500.4
2006	603.0	471.2	522.1	440.9	743.2	489.4
2007	457.6	397.7	402.4	394.6	524.2	391.4
2008	383.0	343.7	390.1	379.9	377.6	313.1
2009	369.3	315.7	382.1	340.7	359.2	294.2
2010	329.8	242.9	325.6	247.7	333.4	238.8
2011	207.2	207.0	137.9	182.4	313.5	197.2
2012	120.3	137.4	68.5	104.3	249.1	124.7
2013	43.0	49.6	32.5	33.7	128.9	70.8

Table 4. Estimated changes in average time to prescription for NSCLC targeted therapies following changes in reimbursement policies

	Impact of erlotinib covered by NHI and gefitinib/erlotinib as second line treatments in 2007 and 2008					Impact of gefitinib as first line treatment in 2011				
	Intercept	Baseline trend	Level change	Trend change	Absolute change (2 year later)	Relative change (2 year later)	Level change	Trend change	Absolute change (2 year later)	Relative change (2 year later)
Average Time to Prescription (days)										
Targeted Therapies (gefitinib+erlotinib)	922.5246	-116.0248 (-131.6088, -100.4408)	--	67.9176 (41.1362, 94.6990)	-9.20% (-9.65%, -8.75%)	-65.84% (-68.30%, -63.37%)	--	-45.3087 (-72.0901, -18.5273)	-90.62 (-144.18, -37.06)	-41.59% (-57.24%, -25.93%)
gefitinib	759.1598	-83.6959 (-100.3257, -67.0661)	--	51.1611 (23.5177, 78.8045)	102.3221 (47.0363, 157.6080)	39.82% (9.87%, 69.77%)	-182.0687 (-245.2401, -118.8973)	--	-182.0690 (-245.2390, -118.8990)	-69.57% (-81.08%, -58.07%)
erlotinib	1905.0000	-362.5991 (-404.6915, -320.5067)	--	316.5921 (260.7650, 372.4192)	633.1842 (521.5322, 744.8362)	-234.37% (-318.17%, -150.57%)	--	--	0.00%	0.00%


Figure Legends

Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib.


Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

For peer review only

(A) Targeted therapies (gefitinib + erlotinib)



(B) Gefitinib



(C) Erlotinib




Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib. Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

134x272mm (300 x 300 DPI)

BMJ Open

Effects of Removing Reimbursement Restrictions on Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022293.R1
Article Type:	Research
Date Submitted by the Author:	18-Sep-2018
Complete List of Authors:	Hsu, Jason C.; National Cheng Kung University, School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine Wei, Chen-Fang ; National Taiwan University Hospital Hsin-Chu Branch, Department of Pharmacy Yang, Szu-Chun ; National Cheng Kung University Hospital, Department of Internal Medicine
Primary Subject Heading:	Health policy
Secondary Subject Heading:	Health services research, Medical management, Public health
Keywords:	Targeted therapies, Lung cancer, Reimbursement policy, Interrupted time series

SCHOLARONE™
Manuscripts

Title Page

Effects of Removing Reimbursement Restrictions on Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Jason C. Hsu¹; Chen-Fang Wei²; Szu-Chun Yang³

1. School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan; 2. Department of Pharmacy, National Taiwan University Hospital Hsin-Chu Branch, Taiwan; 3. Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan

Corresponding author:

Jason C. Hsu, Ph.D.

Email address: jasonhsu@harvard@gmail.com

Postal Address: No.1, Daxue Rd., East Dist., Tainan City 70101, Taiwan (R.O.C.)

Phone: 1-886-985518678

Abstract

Interventions: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for advanced NSCLC patients by Taiwan National Health Insurance (TNHI) in 2004; subsequently it became a second-line (in 2007) and further a first-line (in 2011) therapy for EGFR mutation-positive, advanced NSCLC patients. Another targeted therapy, erlotinib, was initially approved as a third-line therapy in 2007, and it became second-line in 2008.

Objectives: This study is aimed toward an exploration of the impacts of the TNHI reimbursement policies (removing reimbursement restrictions) related to accessibility of targeted therapies.

Setting: We retrieved 2004-2013 claims data for all patients with lung cancer diagnoses from

1
2
3 the National Health Insurance Research Database.

4
5 **Design and Outcome Measures:** Using an interrupted time series design and a segmented
6 regression, we estimated changes in the monthly prescribing rate by patient number and
7 market shares by cost following each modification of the reimbursement policy for gefitinib
8 and erlotinib for NSCLC treatment.
9
10

11
12 **Results:** The prescribing rate of the targeted therapies increased by 15.58%, decreased by
13 10.98%, and increased by 6.31% following the introduction of gefitinib as a second line
14 treatment in 2007, erlotinib as a second line treatment in 2008, and gefitinib as as first line
15 treatment in 2011, respectively. The average time to prescription reduced by 65.84% and
16 41.59% following coverage of erlotinib by insurance and gefitinib/erlotinib as second line
17 treatments in 2007-2008 and following gefitinib as a first line treatment in 2011.
18
19

20
21 **Conclusions:** The changes in the reimbursement policies had significant impacts on the
22 accessibility of targeted therapies for NSCLC treatment. Removing reimbursement
23 restrictions will increase use of that specific drug but may decrease use of other drugs. These
24 interventions also significantly accelerate the time to prescription of targeted therapies.
25
26
27
28
29
30
31

32
33
34 **Keywords:** *Lung cancer, Targeted therapies, Reimbursement policy, Interrupted time series*
35
36
37

38 **Strengths and limitations of this study**

- 39
40
41 ■ This study confirmed that removing reimbursement restrictions for targeted therapies
42 successfully improved drug accessibility.
43
44 ■ In addition to improving the prescription rate, the speed (time to prescription) was also
45 used to measure drug accessibility.
46
47 ■ An interrupted time series design, a strong quasi-experimental method, was applied.
48
49 ■ This study focused on two targeted therapies with similar clinical roles, and it was found
50 that the policy also would tend to decrease use of other drugs.
51
52 ■ During the study period (2004-2013), only first-generation drugs were included, but
53 newer drugs were not.
54
55
56
57
58
59
60

Manuscript

Effects of Removing Reimbursement Restrictions on Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan

Introduction

Lung cancer is the leading cause of cancer deaths worldwide.¹ In the United States, in 2011, approximately 221,130 new cases of lung cancer (14% of all cancer diagnoses) were predicted, out of which 156,940 deaths (27% of cancer deaths) were estimated to have been due to lung cancer.² In Taiwan, lung cancer is also one of the most commonly diagnosed cancers as well as the leading cause of cancer deaths. Approximately 11,692 new cases of lung cancer (12% of all cancer diagnoses) and 8,587 deaths (20% of cancer deaths) were predicted to occur in Taiwan in 2012.³ About 85% of all lung cancers are identified as non-small cell, and approximately 75% of these are metastatic or advanced at diagnosis, for which no curative treatment is available.⁴⁻⁷

Since 2004, oral targeted therapies for non-small cell lung cancer have been launched into the market for epidermal growth factor receptor (EGFR) mutation patients. The EGFR molecular targeted drugs (MTD), gefitinib and erlotinib, were firstly approved as third-line or second-line therapy for advanced NSCLC patients because of their therapeutic benefits, as suggested by randomized clinical trials.⁸⁻¹⁰ The recent National Comprehensive Cancer Network guideline¹¹ further suggests MTD as first-line therapy for EGFR mutation-positive, advanced NSCLC patients based on cumulating evidence showing a significant association between mutated EGFR and the clinical benefits of MTD.¹²⁻¹⁴ In the light of the rapid disease progression associated with advanced NSCLC, access to pharmaceutical innovations such as MTD on a timely basis is vital to patients with the right indications who need it.

According to “Directions for Drug Restricted Benefits for National Health Insurance,” two targeted therapies, gefitinib and erlotinib, used for the treatment of lung cancer have been reimbursed in Taiwan since 2004 and 2007, respectively. When the reimbursement for

1
2
3 gefitinib by health insurance began in November 2004, considering the potential significant
4 impact of its use on the health care drug expenditure budget, it was limited to use only in
5 patients with NSCLC who had previously used platinum and docetaxel or paclitaxel
6 chemotherapy, but who still partially progressed or metastasized (for the third line treatment).
7
8 Later, clinical studies have confirmed that the efficacy and safety of gefitinib are better than
9 those for chemotherapy drugs, and that clinical treatment guidelines are recommended for
10 second-line treatment. To improve the accessibility of drugs and early use of new drugs, in
11 November 2007, Taiwan National Health Insurance began to pay for gefitinib in patients who
12 had previously used first-line platinum-containing chemotherapy, or patients who had
13 received first-line chemotherapy at 70 years of age or older, but were still partially
14 exacerbated or metastatic, as a second line treatment.^{14,15} Finally, for those with EGFR
15 mutation diagnosis, because clinical studies have confirmed that the efficacy of first-line
16 therapy is better than that of posterior therapy, gefitinib has been further allowed to be used as
17 a first-line therapy for EGFR mutation-positive advanced NSCLC patients since June
18 2011.^{12,16,17}

19
20
21 Similarly, considering a limited health care budget, erlotinib has also been limited for use
22 as a third line treatment since June 2007 to patients with NSCLC who had previously used
23 platinum and docetaxel or had undergone paclitaxel chemotherapy, but had still partially
24 progressed or metastasized. Until June 2008, Taiwan National Health Insurance began to pay
25 for erlotinib for patients who had previously undergone first-line platinum-containing
26 chemotherapy, or patients who had received first-line chemotherapy at 70 years of age or
27 older, but were still partially exacerbated or metastatic, as a second line treatment.^{18,19} Finally,
28 for those with EGFR mutation diagnosis, because clinical studies have confirmed that the
29 efficacy of first-line therapy is better than that of posterior therapy, it has been further allowed
30 for use as a first-line therapy for EGFR mutation-positive advanced NSCLC patients since
31 June 2013.²⁰⁻²²

32
33
34 Little is known about the impacts of changes in targeted therapy-related reimbursement
35 policies (related to removing reimbursement restrictions and broadening the eligible patient
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 population) in Taiwan. The aim of our longitudinal analyses was to address this gap by
4 examining the recent trends in utilization of and expenditures for targeted therapies (gefitinib
5 and erlotinib) following changes in the reimbursement policy, which involve the accessibility
6 and economic burden of drugs. Furthermore, we also evaluated the changes in time to
7 prescription of NSCLC over time.
8
9
10
11
12

13 14 15 **Method**

16 *Data sources*

17
18 All monthly claims data, including prescription details and insurer spending, for
19 antineoplastic agents between 2004 and 2013 were retrieved from Taiwan's National Health
20 Insurance Research Database. The database contains information from a nationwide,
21 mandatory-enrollment, single-payer healthcare system created in 1995. Nearly 99% of the
22 Taiwanese population (around 23 million residents) is enrolled, and this system contracts with
23 97% of hospitals and clinics throughout the country. The National Health Insurance (NHI)
24 covers a wide range of prescription medicines as well as inpatient and outpatient medical
25 services.²³ NSCLC-related prescriptions were identified using the International Classification
26 of Diseases, 9th edition (ICD-9) diagnosis codes for cancer (codes: 162). Patients with small
27 cell lung cancer were not included in this study, and patients who had used etoposide and
28 topotecan were excluded.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Drugs of interest*

45 We used the Anatomical Therapeutic Chemical (ATC) classification system from the
46 World Health Organization. We identified all antineoplastic agents using the ATC code
47 "L01." Targeted therapies included in the analysis were protein kinase inhibitors (gefitinib
48 and erlotinib). New targeted therapies (afatinib, crizotinib, and ceritinib) were not included in
49 this study because they were not reimbursed by NHI before 2013.
50
51
52
53
54
55
56
57
58
59
60

Measurements

To examine the trends in the accessibility of the targeted therapies (gefitinib and erlotinib) following the changes in reimbursement policies, we calculated the monthly number of patients who used each targeted therapy and the related costs from 2004 to 2013. Then, we estimated the proportion of their use by patient number and the market share by cost among total patient numbers and total costs of all antineoplastic agents. The prescribing rate of the targeted therapies by patient number was estimated by using the number of patients who had used the targeted therapies divided by the number of patients who had used antineoplastic agents, and the market share of targeted therapies by cost was estimated by using the cost of the targeted therapies divided by the cost of antineoplastic agents. The cost was adjusted using the yearly consumer price index (CPI).²⁴

Statistical Analysis

The interrupted time series design²⁵, a strong quasi-experimental method, was adopted to evaluate the overall changes in drug utilization (prescribing rate and market share of cost) before and after the four modifications to the drug reimbursement policy: (1) erlotinib was covered by NHI in June 2007; (2) gefitinib became available as a second-line treatment in November 2007; (3) erlotinib became available as a second-line treatment in June 2008, and (4) gefitinib became available as a first-line treatment in June 2011. For average time to prescription, we combined the previous three policy changes as one intervention due to the fact that their timing was similar.

A segmented linear regression model was used to estimate post-policy changes in both the level and trend of these study outcomes.²⁶⁻²⁹ Using baseline trends, we projected rates over time with the assumption that the baseline trend reflected what would have happened without the implementation of the promotion strategies. The basic model included terms to estimate the baseline level for each outcome (intercept), baseline trend (slope), changes in the level immediately after policy implementation, and changes in the trend after the policy change.^{25,30} Our models also controlled for autocorrelation.³¹ To identify the most

1
2
3 parsimonious models, we used backward elimination and excluded non-significant terms
4
5 (P>0.05).
6

7 To summarize the results as a single metric, we expressed the policy intervention by
8 using the relative difference between the actual value and the predicted value after the policy
9 intervention, and we estimated the relative changes in the prescription rates and market shares
10 (with 95% confidence intervals, CI)³² in outcomes 3 months following the interventions
11 compared to projected rates. We calculated the relative change by using this formula: “The
12 relative changes = (actual value-predicted value) in outcomes 3 months following the
13 interventions / predicted value in outcomes 3 months following the interventions.”
14
15
16
17
18
19

20
21 In addition, we selected patients who had used the targeted therapies during the study
22 period, and based on the time of newly diagnosed NSCLC, time to prescription was used to
23 represent the length of time required before use of the targeted therapies (representing the
24 speed of drug accessibility). We also calculated the average of the difference between
25 diagnosis date and the date of first use of the targeted therapies for each year over time. The
26 relative changes of the average time to prescription (with 95% confidence intervals, CI)³² in
27 outcomes 2 years following the interventions compared to projected rates were estimated.
28 The relative changes were calculated using the following formula: “The relative changes =
29 (actual value-predicted value) in outcomes 2 years following the interventions / predicted
30 value in outcomes 2 years following the interventions.” All analyses were carried out with
31 SAS software, Version 9.4 (SAS Institute, Cary, NC).
32
33
34
35
36
37
38
39
40
41
42
43

44 ***Patient and Public Involvement***

45 Patients were not involved in this study.
46
47
48
49

50 **Results**

51 52 53 54 ***Prescribing rate of targeted therapies by patient number***

55
56 Table 1 presents the prescribing rate by patient number and the market share by cost of
57
58
59
60

1
2
3 the targeted therapies over time. Overall, the number of patients who had used the targeted
4 therapies (gefitinib and erlotinib) increased from 228 in 2004 to 8,542 in 2013, which
5 accounted for 5.48% of patients who had used antineoplastic agents in 2004 and 58.52% who
6 had used them in 2013. Among these, the number of patients who had used gefitinib
7 increased from 228 (5.48% of patients who used antineoplastic agents) in 2004 to 5,558
8 (38.08%) in 2013; the number of patients who had used erlotinib increased from 499 (8.44%)
9 in 2007 to 2,984 (20.44%) in 2013.

16
17 [Table 1]

20 21 ***Market share of targeted therapies by cost***

22
23 During the 10-year study period, the estimated market share of targeted therapies by cost
24 increased from US\$573,515 in 2004 to US\$57,165,899 in 2013, which accounted for 3.85%
25 in 2004 and 62.38% in 2013 of the cost of antineoplastic agents, respectively. Among these,
26 the cost of gefitinib increased from US\$573,515 (3.85% of cost of antineoplastic agents) in
27 2004 to US\$41,677,315 (45.48%) in 2013; the cost of erlotinib increased from US\$2,694,918
28 (9.13%) in 2007 to US\$15,488,583 (16.9%) in 2013.

36 37 ***Effects of multiple changes in reimbursement policies on the use of targeted therapies***

40 41 **Targeted therapies**

42 The prescribing rate of the targeted therapies remained steady after erlotinib was
43 covered by NHI in June 2007 (Table 2). There was a relative increase of 15.58% in the
44 prescribing rate of the targeted therapies 3 months after gefitinib became available as a
45 second-line treatment in November 2007, while there was a relative reduction of 10.98%
46 after erlotinib became available as a second-line treatment in June 2008. After gefitinib
47 became available as a first line-treatment in June 2011, it's usage rose relatively by 6.31%.
48 Figure 1 (A) shows the prescribing rate of the targeted therapies by patient number over time.

56 The market share of the targeted therapies by cost remained steady after erlotinib was

1
2
3 covered by NHI in June 2007. Gefitinib became available as a second-line treatment in
4
5 November 2007 and became available as a first line-treatment in June 2011. There was a
6
7 relative decline of 4.33% in the market share of the targeted therapies by cost 3 months after
8
9 erlotinib became available as a second-line treatment in June 2008.

10
11 [Table 2] [Figure 1]
12
13

14 15 **Gefitinib**

16
17 The prescribing rate of gefitinib decreased by 20.69% after erlotinib was covered by
18
19 NHI in June 2007. It increased by 54.32%, decreased by 13.27%, and increased by 21.76%
20
21 after gefitinib became available as a second-line treatment in November 2007; erlotinib
22
23 became available as a second-line treatment in June 2008, and gefitinib became available as a
24
25 first-line treatment in June 2011, respectively. Figure 1 (B) shows the prescribing rate of
26
27 gefitinib by patient number over time.

28
29 There was a relative reduction of 6.59% in market share by cost for gefitinib after
30
31 erlotinib was covered by NHI in June 2007. This did not change after gefitinib became
32
33 available as a second-line treatment in November 2007, and erlotinib became a second-line
34
35 treatment in June 2008. However, the market share by cost increased by 16.63% after
36
37 gefitinib became available as a first-line treatment in June 2011.
38
39

40 41 **Erlotinib**

42
43 The prescribing rate of erlotinib declined relatively by 26.79% after gefitinib became
44
45 available as a second line treatment in November 2007. It increased by 22.62% and decreased
46
47 by 10.3% after erlotinib became available as a second line treatment in June 2008, and
48
49 gefitinib became available as a first line treatment in June 2011, respectively. Figure 1 (C)
50
51 shows the prescribing rate of erlotinib by patient number over time.

52
53 There was a relative reduction of 30.33% in market share by cost for erlotinib after
54
55 gefitinib became available as a second line treatment in November 2007. It increased by
56
57 21.66% and decreased by 9.3% after erlotinib became available as a second line treatment in
58
59

1
2
3 June 2008, and gefitinib became available as a first line treatment in June 2011, respectively.
4
5
6

7 *Time to prescriptions of the targeted therapies*

8
9 The average time to prescription of the targeted therapies is shown in Table 3, and the
10 estimated changes in time to prescription following changes in the reimbursement policies are
11 presented in Table 4. The average time to prescription of the targeted therapies rapidly
12 decreased from 802 days (S.D.=654.6) in 2004 to 43 days (S.D.=49.6) in 2013 (Table 3) and
13 reduced by 65.84% after erlotinib was covered by the NHI, and gefitinib/erlotinib became
14 available as second line treatments in 2007 and 2008 and further decreased by 41.59% after
15 gefitinib became available as a first line treatment in 2011 (Table 4). The average time to
16 prescription of gefitinib decreased from 685 days (S.D.=587.4) in 2004 to 33 days (S.D.=33.7)
17 in 2013 (Table 3). There was a relative growth of 39.82% in time to prescription for gefitinib
18 after erlotinib was covered by NHI, and gefitinib/erlotinib became available as second line
19 treatments, while there was a relative decline of 69.57% after gefitinib became a first line
20 treatment (Table 4). The average time to prescription of erlotinib decreased from 1,602 days
21 (S.D.=520.7) in 2004 to 129 days (S.D.=70.8) in 2013 (Table 3). It dropped substantially by
22 234.37% after erlotinib was covered by the NHI, and gefitinib/erlotinib became available as
23 second line treatments, but it did not change after gefitinib became available as a first line
24 treatment (Table 4).
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 [Table 3] [Table 4]
41
42
43

44 **Discussion**

45
46
47
48 In this study, the large NHIRD database was taken advantage of to examine 2004-2013
49 (10 years) of the use of targeted therapies for NSCLC lung cancer. Using a strong
50 quantitative research method (an interrupted time series design), our findings revealed
51 changes in the accessibility of the targeted therapies, including the prescribing rate,
52 prescription speed, and economic burden, following a series of reimbursement policy
53
54
55
56
57
58
59
60

1
2
3 modifications.

4
5 It was found that four interventions had significant various effects on gefitinib and
6 erlotinib use. To understand the impacts of the drug reimbursement policy of “removing
7 reimbursement restrictions and broadening the eligible patient population,” the prescribing
8 rate and prescription speed were used to represent the accessibility of drugs. The results made
9 it possible to determine whether “removing reimbursement restrictions and broadening the
10 eligible patient population” actually allowed more patients to have access to the targeted
11 therapies.
12
13
14
15
16
17

18
19 In the case of gefitinib, the prescribing rate has steadily risen since it was first covered
20 by NHI in 2004. Then, the coverage of erlotinib (as a third line) for NSCLC resulted in a drop
21 in gefitinib by 20% (prescribing rate) and 6% (market share by expenditure). A few months
22 later, when gefitinib became available as a second line treatment, this caused the greatest
23 changes in gefitinib use (a 54.32% reduction). When erlotinib became available as a
24 second-line treatment, gefitinib’s use reduced by 13%. Then, gefitinib’s prescribing rates and
25 expenditures rose again (a 21% increase in prescribing rate and a 17% increase in
26 expenditures) when gefitinib became available as a first line treatment.
27
28
29
30
31
32
33

34
35 In the case of erlotinib, three changes in the reimbursement rules had significant effects
36 on prescribing rates and market share by cost. Especially, after gefitinib became available as a
37 second line treatment, the prescribing rate and market share of cost decreased by 27% and
38 30%, respectively. In addition, the previous rates of erlotinib reduced by 10% and 9%,
39 respectively, after gefitinib became available as a first line treatment. On the other hand,
40 when erlotinib became available as a second line treatment, approximately 23% and 22%
41 increases in prescribing rates and market share by cost were observed, respectively.
42
43
44
45
46
47

48
49 The overall use of oral targeted therapies (gefitinib and erlotinib) did not rise following
50 the introduction of erlotinib in June 2007. However, use significantly rose by 15% when
51 gefitinib became available as a second-line treatment in November 2007, while it fell by 10%
52 when erlotinib became available as a second-line treatment in June 2008. When gefitinib
53 became available as a first-line treatment, the overall prescription rate of oral targeted
54
55
56
57

1
2
3 therapies only increased by 6%. On the other hand, the market share of cost of oral targeted
4 therapies was only slightly diminished when erlotinib became available as a second-line
5 treatment in June 2008, but it was not affected by other interventions. In general, these
6 changes in the reimbursement rules were effective with regard to improving the accessibility
7 of the targeted therapies.
8
9
10
11
12

13 As far as the speed of accessibility of the targeted therapies related to NSCLC treatment,
14 the average time to prescription for targeted therapies gradually reduced from 802 days in
15 2004 to 43 days in 2013. This means the changes in the reimbursement rules (removing
16 reimbursement restriction and broadening the eligible patient population) markedly
17 accelerated the accessibility of the targeted therapies.
18
19
20
21
22

23 This study had several limitations. First, the study focused on the effects of removing
24 reimbursement restrictions and broadening the eligible patient population related to the
25 accessibility of medicines. We used three indicators: prescribing rate, market share of cost,
26 and time to prescription, as measurements of accessibility of medicine. Due to the lack of
27 clinical test data in the Taiwan NHIRD claims database, this study was not able to identify
28 patients' eligibility to obtain the targeted therapies based on clinical testing (such as
29 pathology or cytological results and EGFR-TK gene mutation test results, etc.). Secondly, in
30 this study, data from the Taiwan NHIRD claims database was analyzed that did not cover data
31 for payments made by the patients themselves. Hence, there may be differences between the
32 estimated prescription rate / costs and the actual value. However, this gap is not believed to
33 be very significant since the proportion of payments made by patients themselves was very
34 small. Third, considering the timing of drug launches, during the study period (2004-2013),
35 only two first-generation targeted therapies (gefitinib and erlotinib) could be included, and
36 newer medicines were out of the scope of this study. Finally, this study was aimed toward an
37 examination of the effects of removing reimbursement restrictions and broadening the
38 eligible patient population related to accessibility to the targeted therapies. Further studies
39 about how such policies affect the clinical outcomes of treatments and the cost-effectiveness
40 of the policies are needed in the future.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

The present study examined how multiple, separate changes in reimbursement policies have changed drug utilization and accessibility of the targeted therapies. Overall, removing reimbursement restrictions and broadening eligible the patient population for NSCLC targeted therapies improved the accessibility of such medications. In detail, when a targeted therapy became available for either early or broad use, utilization increased, but this may have in turn decreased the use of other drugs in a similar class. In addition, the targeted therapies were prescribed earlier once their insurance reimbursement restrictions were lifted. The results of this study can be used as the empirical basis for clinical treatment, to help enhance the content of academic literature on this subject, and can serve as the empirical basis for future targeted therapy studies.

■ Author Contributions

JCH and SCY conceptualized and designed the study. CFW collected data, performed analysis, and drafted the manuscript. JCH and SCY reviewed all data and revised the manuscript critically for intellectual content. All authors approved the final version for submission.

■ Competing Interests

The authors have no competing interests.

■ Funding

Dr. Hsu was supported by Taiwan Ministry of Science and Technology grants (Grant ID: MOST 104-2320-B-006-005, MOST 106-2320-B-006-039). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

■ Data Sharing Statement

The authors have obtained nationwide, monthly claims data for NSCLC patients, from 2004 to 2013, from the Taiwan National Health Insurance Research Database (NHIRD). NHIRD does not permit external sharing of any of the data elements. No additional data available.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893-917.
2. American Cancer Society: Cancer Facts & Figures 2012. Atlanta: American Cancer Society. 2012.
3. Cancer Registry Annual Report, 2011, Taiwan. Health Promotion Administration, Ministry of Health and Welfare 2014.
4. Pfizer Oncology, Lung cancer fact sheet. 2012.
5. Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. *Biologics* 2009;3:215-24.
6. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. *Expert Rev Anticancer Ther* 2007;7:1423-37.
7. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-23.
8. Chen HL, Shen LJ, Wei CP, Lu HM, Hsiao FY. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients. *J Eval Clin Pract* 2015;21:808-16.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005;353:123-32.
10. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. *N Engl J Med* 2011;364:947-55.
11. NCCN Clinical Practice Guidelines in Oncology (2013) Non-Small Cell Lung Cancer, p. 2. National Comprehensive Cancer Network. Available at: <http://www.nccn.org/index.asp> [accessed on Dec. 19,2015].
12. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8.
13. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. *Jpn J Clin Oncol* 2009;39:137-50.
14. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
15. Sun JM, Lee KH, Kim SW, et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. *Cancer* 2012;118:6234-42.
16. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8.
17. Wu YL, Chu DT, Han B, et al. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced

- 1
2
3 non-small-cell lung cancer: evaluation of patients recruited from mainland China. *Asia Pac J Clin Oncol* 2012;8:232-43.
- 4
5 18. Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in
6 patients with advanced non-small cell lung cancer who failed previous chemotherapy. *Lung*
7 *Cancer* 2012;75:82-8.
- 8
9 19. Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study Comparing Gefitinib
10 With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG
11 5108L. *J Clin Oncol* 2016;34:3248-57.
- 12
13 20. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for
14 patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
15 CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*
16 2011;12:735-42.
- 17
18 21. Haspinger ER, Agustoni F, Torri V, et al. Is there evidence for different effects among
19 EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs)
20 versus chemotherapy as first-line treatment for patients harboring EGFR mutations. *Crit Rev*
21 *Oncol Hematol* 2015;94:213-27.
- 22
23 22. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic
24 non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical
25 trials. *Oncologist* 2015;20:400-10.
- 26
27 23. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug
28 copayment policy in the elderly. *Med Care* 2003;41:1331-42.
- 29
30 24. Analytic Hierarchy Process: Theory and Practice. 2009. (Accessed December 15, 2017,
31 at ftp://mail.im.tku.edu.tw/Prof_Shyur/AHP/AHP2009.pdf).
- 32
33 25. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of
34 interrupted time series studies in medication use research. *J Clin Pharm Ther*
35 2002;27:299-309.
- 36
37 26. Lu CY, Ross-Degnan D, Stephens P, Liu B, Wagner AK. Changes in use of antidiabetic
38 medications following price regulations in China (1999–2009). *Journal of Pharmaceutical*
39 *Health Services Research* 2013;4:3-11.
- 40
41 27. Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and
42 suicidal behavior after FDA warnings and media coverage: quasi-experimental study. *BMJ*
43 2014;348:g3596.
- 44
45 28. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug
46 reimbursement reductions on utilization and expenditures of oral antidiabetic medications in
47 Taiwan: an interrupted time series study. *Health Policy* 2014;116:196-205.
- 48
49 29. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a
50 Medicaid prior authorization policy on access to medications for bipolar illness. *Med Care*
51 2010;48:4-9.
- 52
53 30. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the
54 management and outcomes of hypertension in the United Kingdom: interrupted time series
55 study. *BMJ* 2011;342:d108.
- 56
57 31. Shadish WC, T.; Campbell, D. *Experimental and Quasi-experimental Designs for*

1
2
3 Generalized Causal Inference Houghton Mifflin 2002.

4 32. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating
5 confidence intervals in interrupted time series analyses of health interventions. J Clin
6 Epidemiol 2009;62:143-8.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Prescription rate by patient number and market share by costs of targeted therapies over time (2004-2013)

	Prescription rate by patient number							Market share by costs						
	Number of patients who used antineoplastic agents	Number of patients who used gefitinib	(%)	Number of patients who used erlotinib	(%)	Number of patient who used targeted therapies (gefitinib + erlotinib)	(%)	Cost of antineoplastic agents (US\$)	Cost of gefitinib (US\$)	(%)	Cost of erlotinib (US\$)	(%)	Cost of Targeted therapies (gefitinib + erlotinib) (US\$)	(%)
2004	4,162	228	5.48	0	0.00	228	5.48	14,887,913	573,515	3.85	0	0.00	573,515	3.85
2005	4,876	872	17.88	0	0.00	872	17.88	22,446,991	8,015,889	35.71	0	0.00	8,015,889	35.71
2006	5,173	1095	21.17	0	0.00	1095	21.17	27,126,263	10,435,769	38.47	0	0.00	10,435,769	38.47
2007	5,909	1413	23.91	499	8.44	1912	32.36	29,531,282	12,265,156	41.53	2,694,918	9.13	14,960,074	50.66
2008	7,130	1975	27.70	1418	19.89	3393	47.59	43,162,957	18,784,869	43.52	11,190,711	25.93	29,975,581	69.45
2009	7,673	1922	25.05	2090	27.24	4012	52.29	48,988,605	17,276,102	35.27	18,099,806	36.95	35,375,908	72.21
2010	8,200	2058	25.10	2445	29.82	4503	54.91	51,384,668	16,242,224	31.61	20,207,860	39.33	36,450,084	70.94
2011	10,254	3440	33.55	2754	26.86	6194	60.41	58,115,193	20,942,858	36.04	19,298,723	33.21	40,241,581	69.24
2012	12,621	5011	39.70	3029	24.00	8040	63.70	76,127,283	36,628,520	48.11	17,785,455	23.36	54,413,975	71.48
2013	14,597	5558	38.08	2984	20.44	8542	58.52	91,642,044	41,677,315	45.48	15,488,583	16.90	57,165,899	62.38

Table 2. Estimated changes in targeted therapies utilization following changes in reimbursement policies using segmented regression models

	Intercept	Effects of intervention (1) erlotinib covered by NHI (third line) [200706]				Effects of intervention (2) gefitinib became second line treatment [200711]			Effects of intervention (3) erlotinib became second line treatment [200806]			Effects of intervention (4) gefitinib became first line treatment [201106]		
		Baseline trend	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)
Prescribing rate of targeted therapies	0.0342	0.0041 (0.0021, 0.0060)	NS	NS	NS	NS	0.0121 (0.0027, 0.0215)	15.58%	NS	-0.0140 (-0.0226, -0.0054)	0.0264 (0.0037, 0.0491)	NS	6.31%	
Prescribing rate of gefitinib	0.0263	0.0042 (0.0017, 0.0067)	NS	-0.0146 (-0.0268, -0.0024)	-20.69%	NS	0.0210 (0.0048, 0.0372)	54.32%	NS	-0.0112 (-0.0211, -0.0013)	0.0215 (0.0026, 0.0404)	0.0072 (0.0032, 0.0113)	21.76%	
Prescribing rate of erlotinib	0.0099	0.0127 (0.0059, 0.0195)	NA	NA	NA	NS	-0.0100 (-0.0173, -0.0026)	-26.79%	0.0228 (0.0060, 0.0396)	NS	22.62%	NS	-0.0076 (-0.0105, -0.0048)	
Market share by cost for targeted therapies	0.0446	0.0068 (0.0045, 0.0091)	NS	NS	0	NS	NS	0	NS	-0.0062 (-0.0095, -0.0028)	-4.33%	NS	NS	0
Market share by cost for gefitinib	0.1030	0.0043 (0.0014, 0.0072)	NS	-0.0064 (-0.0106, -0.0022)	-6.59%	NS	NS	0	NS	NS	0	NS	0.0095 (0.0052, 0.0138)	16.63%

Table 3. Time to prescription of targeted therapies for non-small cell lung cancer treatment over time (2004-2013)

	Time to Prescription (days)					
	Targeted therapies (gefitinib + erlotinib)		Gefitinib		Erlotinib	
	Mean	S.D.	Mean	S.D.	Mean	S.D.
2004	801.7	654.6	685.3	587.4	1,602.0	520.7
2005	683.4	546.2	570.0	497.4	1,128.7	500.4
2006	603.0	471.2	522.1	440.9	743.2	489.4
2007	457.6	397.7	402.4	394.6	524.2	391.4
2008	383.0	343.7	390.1	379.9	377.6	313.1
2009	369.3	315.7	382.1	340.7	359.2	294.2
2010	329.8	242.9	325.6	247.7	333.4	238.8
2011	207.2	207.0	137.9	182.4	313.5	197.2
2012	120.3	137.4	68.5	104.3	249.1	124.7
2013	43.0	49.6	32.5	33.7	128.9	70.8

Table 4. Estimated changes in average time to prescription for NSCLC targeted therapies following changes in reimbursement policies

	Impact of erlotinib covered by NHI and gefitinib/erlotinib as second line treatments in 2007 and 2008			Impact of gefitinib as first line treatment in 2011				
	Intercept	Baseline trend	Level change	Trend change	Relative change (2 year later)	Level change	Trend change	Relative change (2 year later)
Average Time to Prescription (days)								
Targeted Therapies (gefitinib+erlotinib)	922.5246	-116.0248 (-131.6088, -100.4408)	NS	67.9176 (41.1362, 94.6990)	-65.84% (-68.30%, -63.37%)	NS	-45.3087 (-72.0901, -18.5273)	-41.59% (-57.24%, -25.93%)
gefitinib	759.1598	-83.6959 (-100.3257, -67.0661)	NS	51.1611 (23.5177, 78.8045)	39.82% (9.87%, 69.77%)	-182.0687 (-245.2401, -118.8973)	NS	-69.57% (-81.08%, -58.07%)
erlotinib	1905.0000	-362.5991 (-404.6915, -320.5067)	NS	316.5921 (260.7650, 372.4192)	-234.37% (-318.17%, -150.57%)	NS	NS	0.00%
Survival Rate (%)								
One year survival	0.4038	0.0173 (0.0151, 0.0195)	NS	NS	0.00%	NS	NS	0.00%
Two year survival	0.2243	0.0186 (0.0164, 0.0208)	NS	NS	0.00%	NS	NS	0.00%

The relative changes = (actual value-predicted value) in outcomes 2 years following the interventions / predicted value in outcomes 2 years following the interventions

NS = not significant; NA=not available

Figure Legends

Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib.

Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

For peer review only




(A) Targeted therapies (gefitinib + erlotinib)**(B) Gefitinib****(C) Erlotinib**

Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib. Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

134x272mm (300 x 300 DPI)

BMJ Open

Effects of Removing Reimbursement Restrictions on Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan: an Interrupted Time Series Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022293.R2
Article Type:	Research
Date Submitted by the Author:	03-Dec-2018
Complete List of Authors:	Hsu, Jason C.; National Cheng Kung University, School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine Wei, Chen-Fang ; National Taiwan University Hospital Hsin-Chu Branch, Department of Pharmacy Yang, Szu-Chun ; National Cheng Kung University Hospital, Department of Internal Medicine
Primary Subject Heading:	Health policy
Secondary Subject Heading:	Health services research, Medical management, Public health
Keywords:	Targeted therapies, Lung cancer, Reimbursement policy, Interrupted time series

SCHOLARONE™
Manuscripts

Title Page

Effects of Removing Reimbursement Restrictions on Targeted Therapy Accessibility for Non-small Cell Lung Cancer Treatment in Taiwan: an Interrupted Time Series Study

Jason C. Hsu¹; Chen-Fang Wei²; Szu-Chun Yang³

1. School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Taiwan; 2. Department of Pharmacy, National Taiwan University Hospital Hsin-Chu Branch, Taiwan; 3. Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan

Corresponding author:

Jason C. Hsu, Ph.D.

Email address: jasonhsu@harvard@gmail.com

Postal Address: No.1, Daxue Rd., East Dist., Tainan City 70101, Taiwan (R.O.C.)

Phone: 1-886-985518678

Abstract

Interventions: Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for advanced NSCLC patients by Taiwan National Health Insurance (TNHI) in 2004; subsequently it became a second-line (in 2007) and further a first-line (in 2011) therapy for EGFR mutation-positive, advanced NSCLC patients. Another targeted therapy, erlotinib, was initially approved as a third-line therapy in 2007, and it became second-line in 2008.

Objectives: This study is aimed toward an exploration of the impacts of the TNHI reimbursement policies (removing reimbursement restrictions) related to accessibility of targeted therapies.

Setting: We retrieved 2004-2013 claims data for all patients with lung cancer diagnoses from

1
2
3
4 the National Health Insurance Research Database.

5
6 **Design and Outcome Measures:** Using an interrupted time series design and a segmented
7
8 regression, we estimated changes in the monthly prescribing rate by patient number and
9
10 market shares by cost following each modification of the reimbursement policy for gefitinib
11
12 and erlotinib for NSCLC treatment.

13
14 **Results:** Totally 92,220 patients with NSCLC were identified. The prescribing rate of the
15
16 targeted therapies increased by 15.58%, decreased by 10.98%, and increased by 6.31%
17
18 following the introduction of gefitinib as a second line treatment in 2007, erlotinib as a
19
20 second line treatment in 2008, and gefitinib as as first line treatment in 2011, respectively.
21
22 The average time to prescription reduced by 65.84% and 41.59% following coverage of
23
24 erlotinib by insurance and gefitinib/erlotinib as second line treatments in 2007-2008 and
25
26 following gefitinib as a first line treatment in 2011.

27
28 **Conclusions:** The changes in the reimbursement policies had significant impacts on the
29
30 accessibility of targeted therapies for NSCLC treatment. Removing reimbursement
31
32 restrictions can significantly increase the level and the speed of drug accessibility.

33
34
35
36
37 **Keywords:** *Lung cancer, Targeted therapies, Reimbursement policy, Interrupted time series*

38 39 40 41 **Strengths and limitations of this study**

- 42
43 ■ Both prescription rate and speed (time to prescription) was used to measure drug
44
45 accessibility.
- 46
47 ■ An interrupted time series design, a strong quasi-experimental method, was applied.
- 48
49 ■ A segmented linear regression model was used to estimate post-policy changes in both
50
51 the level and trend of these study outcomes.
- 52
53 ■ Data from the Taiwan NHIRD claims database was analyzed that did not cover data for
54
55 payments made by the patients themselves.
- 56
57
58
59
60

Manuscript

Introduction

Lung cancer is the leading cause of cancer deaths worldwide.¹ In the United States, in 2011, approximately 221,130 new cases of lung cancer (14% of all cancer diagnoses) were predicted, out of which 156,940 deaths (27% of cancer deaths) were estimated to have been due to lung cancer.² In Taiwan, lung cancer is also one of the most commonly diagnosed cancers as well as the leading cause of cancer deaths. Approximately 11,692 new cases of lung cancer (12% of all cancer diagnoses) and 8,587 deaths (20% of cancer deaths) were predicted to occur in Taiwan in 2012.³ About 85% of all lung cancers are identified as non-small cell, and approximately 75% of these are metastatic or advanced at diagnosis, for which no curative treatment is available.⁴⁻⁷

Since 2004, oral targeted therapies for non-small cell lung cancer (NSCLC) have been launched into the market for epidermal growth factor receptor (EGFR) mutation patients in Taiwan. Two targeted drugs, gefitinib and erlotinib, were firstly approved as third-line therapy for advanced NSCLC patients by Taiwan Food and Drug Administration, based on the results of randomized clinical trials.⁸⁻¹⁰ For advanced NSCLC patients with EGFR mutation-positive, two drugs were furtherly suggested to be used as first-line therapy for them by the recent National Comprehensive Cancer Network guideline¹¹, according to the cumulating evidence showing a significant association between mutated EGFR and their clinical benefits^{8,12-14}

According to “Directions for Drug Restricted Benefits for National Health Insurance,” gefitinib and erlotinib for the treatment of lung cancer have been reimbursed in Taiwan since 2004 and 2007, respectively. When the reimbursement for gefitinib by health insurance began in November 2004, considering the potential significant impact of its use on the health care drug expenditure budget, it was limited to use only in patients with NSCLC who had previously used platinum and docetaxel or paclitaxel chemotherapy, but who still partially progressed or metastasized (for the third line treatment). Later, clinical studies have confirmed that the efficacy and safety of gefitinib are better than those for chemotherapy drugs, and that clinical treatment guidelines are recommended for second-line treatment. To improve the

1
2
3
4 accessibility of drugs and early use of new drugs, in November 2007, Taiwan National Health
5 Insurance began to pay for gefitinib in patients who had previously used first-line
6 platinum-containing chemotherapy, or patients who had received first-line chemotherapy at 70
7 years of age or older, but were still partially exacerbated or metastatic, as a second line
8 treatment.^{14,15} Finally, for those with EGFR mutation diagnosis, because clinical studies have
9 confirmed that the efficacy of first-line therapy is better than that of posterior therapy,
10 gefitinib has been further allowed to be used as a first-line therapy for EGFR
11 mutation-positive advanced NSCLC patients since June 2011.^{12,16,17} Similarly, erlotinib has
12 also been limited for use as a third line treatment since June 2007, it has been further allowed
13 for use as a first-line therapy for EGFR mutation-positive advanced NSCLC patients since
14 June 2013.¹⁸⁻²²

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Little is known about the impacts of changes in targeted therapy-related reimbursement policies (related to removing reimbursement restrictions and broadening the eligible patient population) in Taiwan. The aim of our longitudinal analyses was to address this gap by examining the recent trends in utilization of and expenditures for targeted therapies (gefitinib and erlotinib) following changes in the reimbursement policy, which involve the accessibility and economic burden of drugs. Furthermore, we also evaluated the changes in time to prescription of NSCLC over time.

43 **Method**

44 ***Data sources***

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
All monthly claims data, including prescription details and insurer spending, for antineoplastic agents between 2004 and 2013 were retrieved from Taiwan's National Health Insurance Research Database (NHIRD). The database contains information from a nationwide, mandatory-enrollment, single-payer healthcare system created in 1995. Nearly 99% of the Taiwanese population (around 23 million residents) is enrolled, and this system contracts with 97% of hospitals and clinics throughout the country. The National Health Insurance (NHI) covers a wide range of prescription medicines as well as inpatient and outpatient medical

1
2
3
4 services.²³ NSCLC-related prescriptions were identified using the International Classification
5 of Diseases, 9th edition (ICD-9) diagnosis codes for cancer (codes: 162). Patients with small
6 cell lung cancer were not included in this study, and patients who had used etoposide and
7 topotecan were excluded.
8
9
10

11 12 13 14 ***Drugs of interest***

15
16 We used the Anatomical Therapeutic Chemical (ATC) classification system from the
17 World Health Organization. We identified all antineoplastic agents using the ATC code
18 “L01.” Targeted therapies included in the analysis were protein kinase inhibitors (gefitinib
19 and erlotinib). New targeted therapies (afatinib, crizotinib, and ceritinib) were not included in
20 this study because they were not reimbursed by NHI before 2013.
21
22
23
24
25
26
27

28 29 ***Measurements***

30
31 To examine the trends in the accessibility of the targeted therapies (gefitinib and
32 erlotinib) following the changes in reimbursement policies, we calculated the monthly
33 number of patients who used each targeted therapy and the related costs from 2004 to 2013.
34 Then, we estimated the proportion of their use by patient number and the market share by
35 cost among total patient numbers and total costs of all antineoplastic agents. The prescribing
36 rate of the targeted therapies by patient number was estimated by using the number of
37 patients who had used the targeted therapies divided by the number of patients who had used
38 antineoplastic agents, and the market share of targeted therapies by cost was estimated by
39 using the cost of the targeted therapies divided by the cost of antineoplastic agents. The cost
40 was adjusted using the yearly consumer price index (CPI).²⁴
41
42
43
44
45
46
47
48
49
50
51
52

53 54 ***Statistical Analysis***

55
56 The interrupted time series design²⁵, a strong quasi-experimental method, was adopted
57 to evaluate the overall changes in drug utilization (prescribing rate and market share of cost)
58 before and after the four modifications to the drug reimbursement policy: (1) erlotinib was
59
60

1
2
3
4 covered by NHI in June 2007; (2) gefitinib became available as a second-line treatment in
5
6 November 2007; (3) erlotinib became available as a second-line treatment in June 2008, and
7
8 (4) gefitinib became available as a first-line treatment in June 2011. For average time to
9
10 prescription, we combined the previous three policy changes as one intervention due to the
11
12 fact that their timing was similar.

13
14 A segmented linear regression model was used to estimate post-policy changes in both
15
16 the level and trend of these study outcomes.²⁶⁻²⁹ Using baseline trends, we projected rates
17
18 over time with the assumption that the baseline trend reflected what would have happened
19
20 without the implementation of the promotion strategies. The basic model included terms to
21
22 estimate the baseline level for each outcome (intercept) (β_0), baseline trend (slope) (β_1),
23
24 changes in the level immediately after policy implementation (β_2), and changes in the trend
25
26 after the policy change (β_3) (see the following model).^{25,30} Our models also controlled for
27
28 autocorrelation.³¹ To identify the most parsimonious models, we used backward elimination
29
30 and excluded non-significant terms ($P > 0.05$).

$$Y_t = \beta_0 + \beta_1 * \text{time}_t + \beta_2 * \text{intervention}_t + \beta_3 * \text{time_after_intervention}_t + e_t^{25}$$

31
32
33 To summarize the results as a single metric, we expressed the policy intervention by
34
35 using the relative difference between the actual value and the predicted value after the policy
36
37 intervention, and we estimated the relative changes in the prescription rates and market shares
38
39 (with 95% confidence intervals, CI)³² in outcomes 3 months following the interventions
40
41 compared to projected rates. We calculated the relative change by using this formula: “The
42
43 relative changes = (actual value-predicted value) in outcomes 3 months following the
44
45 interventions / predicted value in outcomes 3 months following the interventions.”

46
47
48 In addition, we selected patients who had used the targeted therapies during the study
49
50 period, and based on the time of newly diagnosed NSCLC, time to prescription was used to
51
52 represent the length of time required before use of the targeted therapies (representing the
53
54 speed of drug accessibility). We also calculated the average of the difference between
55
56 diagnosis date and the date of first use of the targeted therapies for each year over time. The
57
58 relative changes of the average time to prescription (with 95% confidence intervals, CI)³² in
59
60

1
2
3
4 outcomes 2 years following the interventions compared to projected rates were estimated.
5
6 The relative changes were calculated using the following formula: “The relative changes =
7
8 (actual value-predicted value) in outcomes 2 years following the interventions / predicted
9
10 value in outcomes 2 years following the interventions.” All analyses were carried out with
11
12 SAS software, Version 9.4 (SAS Institute, Cary, NC).
13
14
15

16 ***Patient and Public Involvement***

17
18 Patients were not involved in this study.
19
20
21

22 **Results**

23 ***Prescribing rate of targeted therapies by patient number***

24
25
26 Claims data about totally 92,220 patients with NSCLC were collected. Table 1 presents
27
28 the prescribing rate by patient number and the market share by cost of the targeted therapies
29
30 over time. Overall, the number of patients who had used the targeted therapies (gefitinib and
31
32 erlotinib) increased from 228 in 2004 to 8,542 in 2013, which accounted for 5.48% of
33
34 patients who had used antineoplastic agents in 2004 and 58.52% who had used them in 2013.
35
36 Among these, the number of patients who had used gefitinib increased from 228 (5.48% of
37
38 patients who used antineoplastic agents) in 2004 to 5,558 (38.08%) in 2013; the number of
39
40 patients who had used erlotinib increased from 499 (8.44%) in 2007 to 2,984 (20.44%) in
41
42 2013.
43
44

45 [Table 1]
46
47
48

49 ***Market share of targeted therapies by cost***

50
51 During the 10-year study period, the estimated market share of targeted therapies by cost
52
53 increased from US\$573,515 in 2004 to US\$57,165,899 in 2013, which accounted for 3.85%
54
55 in 2004 and 62.38% in 2013 of the cost of antineoplastic agents, respectively. Among these,
56
57 the cost of gefitinib increased from US\$573,515 (3.85% of cost of antineoplastic agents) in
58
59 2004 to US\$41,677,315 (45.48%) in 2013; the cost of erlotinib increased from US\$2,694,918
60

(9.13%) in 2007 to US\$15,488,583 (16.9%) in 2013.

Effects of multiple changes in reimbursement policies on the use of targeted therapies

Targeted therapies

The prescribing rate of the targeted therapies remained steady after erlotinib was covered by NHI in June 2007 (Table 2). There was a relative increase of 15.58% in the prescribing rate of the targeted therapies 3 months after gefitinib became available as a second-line treatment in November 2007, while there was a relative reduction of 10.98% after erlotinib became available as a second-line treatment in June 2008. After gefitinib became available as a first line-treatment in June 2011, its usage rose relatively by 6.31%. Figure 1 (A) shows the prescribing rate of the targeted therapies by patient number over time.

The market share of the targeted therapies by cost remained steady after erlotinib was covered by NHI in June 2007. Gefitinib became available as a second-line treatment in November 2007 and became available as a first line-treatment in June 2011. There was a relative decline of 4.33% in the market share of the targeted therapies by cost 3 months after erlotinib became available as a second-line treatment in June 2008.

[Table 2] [Figure 1]

Gefitinib

The prescribing rate of gefitinib decreased by 20.69% after erlotinib was covered by NHI in June 2007. It increased by 54.32%, decreased by 13.27%, and increased by 21.76% after gefitinib became available as a second-line treatment in November 2007; erlotinib became available as a second-line treatment in June 2008, and gefitinib became available as a first-line treatment in June 2011, respectively. Figure 1 (B) shows the prescribing rate of gefitinib by patient number over time.

There was a relative reduction of 6.59% in market share by cost for gefitinib after erlotinib was covered by NHI in June 2007. This did not change after gefitinib became available as a second-line treatment in November 2007, and erlotinib became a second-line

1
2
3
4 treatment in June 2008. However, the market share by cost increased by 16.63% after
5 gefitinib became available as a first-line treatment in June 2011.
6
7
8
9

10 **Erlotinib**

11
12 The prescribing rate of erlotinib declined relatively by 26.79% after gefitinib became
13 available as a second line treatment in November 2007. It increased by 22.62% and decreased
14 by 10.3% after erlotinib became available as a second line treatment in June 2008, and
15 gefitinib became available as a first line treatment in June 2011, respectively. Figure 1 (C)
16 shows the prescribing rate of erlotinib by patient number over time.
17
18
19
20
21

22 There was a relative reduction of 30.33% in market share by cost for erlotinib after
23 gefitinib became available as a second line treatment in November 2007. It increased by
24 21.66% and decreased by 9.3% after erlotinib became available as a second line treatment in
25 June 2008, and gefitinib became available as a first line treatment in June 2011, respectively.
26
27
28
29
30
31
32

33 ***Time to prescriptions of the targeted therapies***

34
35 The average time to prescription of the targeted therapies is shown in Table 3, and the
36 estimated changes in time to prescription following changes in the reimbursement policies are
37 presented in Table 4. The average time to prescription of the targeted therapies rapidly
38 decreased from 802 days (S.D.=654.6) in 2004 to 43 days (S.D.=49.6) in 2013 (Table 3) and
39 reduced by 65.84% after erlotinib was covered by the NHI, and gefitinib/erlotinib became
40 available as second line treatments in 2007 and 2008 and further decreased by 41.59% after
41 gefitinib became available as a first line treatment in 2011 (Table 4). The average time to
42 prescription of gefitinib decreased from 685 days (S.D.=587.4) in 2004 to 33 days (S.D.=33.7)
43 in 2013 (Table 3). There was a relative growth of 39.82% in time to prescription for gefitinib
44 after erlotinib was covered by NHI, and gefitinib/erlotinib became available as second line
45 treatments, while there was a relative decline of 69.57% after gefitinib became a first line
46 treatment (Table 4). The average time to prescription of erlotinib decreased from 1,602 days
47 (S.D.=520.7) in 2004 to 129 days (S.D.=70.8) in 2013 (Table 3). It dropped substantially by
48
49
50
51
52
53
54
55
56
57
58
59
60

234.37% after erlotinib was covered by the NHI, and gefitinib/erlotinib became available as second line treatments, but it did not change after gefitinib became available as a first line treatment (Table 4).

[Table 3] [Table 4]

Discussion

The drug accessibility has become a favorite topic for analysis of drug utilization, especially the accessibility of expensive cancer target drugs is the most noticed.³³⁻³⁵ Although some high-priced drugs have been approved for marketing, the reimbursement restriction from health insurance is an obstacle to drug accessibility.^{36,37} In this study, the data from NHIRD was used to examine the utilization of targeted therapies for NSCLC during 2004-2013 (10 years). Using a strong quantitative research method (an interrupted time series design), our findings revealed changes in the accessibility of the targeted therapies, including the prescribing rate, prescription speed, and economic burden, following a series of reimbursement policy modifications.

It was found that four interventions had significant various effects on gefitinib and erlotinib use. To understand the impacts of the drug reimbursement policy of “removing reimbursement restrictions and broadening the eligible patient population,” the prescribing rate and prescription speed were used to represent the accessibility of drugs. The results made it possible to determine whether “removing reimbursement restrictions and broadening the eligible patient population” actually allowed more patients to have access to the targeted therapies.

In the case of gefitinib, the prescribing rate has steadily risen since it was first covered by NHI in 2004. Then, the coverage of erlotinib (as a third line) for NSCLC resulted in a drop in gefitinib by 20% (prescribing rate) and 6% (market share by expenditure). A few months later, when gefitinib became available as a second line treatment, this caused the greatest changes in gefitinib use (a 54.32% increase). When erlotinib became available as a second-line treatment, gefitinib’s use reduced by 13%. Then, gefitinib’s prescribing rates and

1
2
3
4 expenditures rose again (a 21% increase in prescribing rate and a 17% increase in
5 expenditures) when gefitinib became available as a first line treatment.
6

7
8 In the case of erlotinib, three changes in the reimbursement rules had significant effects
9 on prescribing rates and market share by cost. Especially, after gefitinib became available as
10 a second line treatment, the prescribing rate and market share of cost decreased by 27% and
11 30%, respectively. In addition, the previous rates of erlotinib reduced by 10% and 9%,
12 respectively, after gefitinib became available as a first line treatment. On the other hand,
13 when erlotinib became available as a second line treatment, approximately 23% and 22%
14 increases in prescribing rates and market share by cost were observed, respectively.
15
16
17
18
19
20
21

22 The overall use of oral targeted therapies (gefitinib and erlotinib) did not rise following
23 the introduction of erlotinib in June 2007. However, use significantly rose by 15% when
24 gefitinib became available as a second-line treatment in November 2007, while it fell by 10%
25 when erlotinib became available as a second-line treatment in June 2008. When gefitinib
26 became available as a first-line treatment, the overall prescription rate of oral targeted
27 therapies only increased by 6%. On the other hand, the market share of cost of oral targeted
28 therapies was only slightly diminished when erlotinib became available as a second-line
29 treatment in June 2008, but it was not affected by other interventions. In general, these
30 changes in the reimbursement rules were effective with regard to improving the accessibility
31 of the targeted therapies.
32
33
34
35
36
37
38
39
40
41
42

43 As far as the speed of accessibility of the targeted therapies related to NSCLC treatment,
44 the average time to prescription for targeted therapies gradually reduced from 802 days in
45 2004 to 43 days in 2013. This means the changes in the reimbursement rules (removing
46 reimbursement restriction and broadening the eligible patient population) markedly
47 accelerated the accessibility of the targeted therapies.
48
49
50
51
52

53 Past research indicates that the accessibility of a drug is related to the health insurance
54 coverage proportion.^{37,38} This study used targeted therapy's accessibility for NSCLC
55 treatment as an example, it further proved that in health insurance, removing reimbursement
56 restrictions can significantly increase the accessibility of drugs and the speed of accessibility
57
58
59
60

1
2
3
4 of drugs. Although the accessibility of drugs has increased through changes in health
5 insurance policies, health care resource allocation and health inequalities between various
6 cancer types or diseases are issues that need to be subsequently followed up.
7
8

9
10 This study had several limitations. First, the study focused on the effects of removing
11 reimbursement restrictions and broadening the eligible patient population related to the
12 accessibility of medicines. We used three indicators: prescribing rate, market share of cost,
13 and time to prescription, as measurements of accessibility of medicine. Due to the lack of
14 clinical test data in the Taiwan NHIRD claims database, this study was not able to identify
15 patients' eligibility to obtain the targeted therapies based on clinical testing (such as
16 pathology or cytological results and EGFR-TK gene mutation test results, etc.). Secondly, in
17 this study, data from the Taiwan NHIRD claims database was analyzed that did not cover
18 data for payments made by the patients themselves. Hence, there may be differences between
19 the estimated prescription rate / costs and the actual value. However, this gap is not believed
20 to be very significant since the proportion of payments made by patients themselves was very
21 small. Third, considering the timing of drug launches, during the study period (2004-2013),
22 only two first-generation targeted therapies (gefitinib and erlotinib) could be included, and
23 newer medicines were out of the scope of this study. Finally, this study was aimed toward an
24 examination of the effects of removing reimbursement restrictions and broadening the
25 eligible patient population related to accessibility to the targeted therapies. Further studies
26 about how such policies affect the clinical outcomes of treatments and the cost-effectiveness
27 of the policies are needed in the future.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Conclusion**

50
51 The present study examined how multiple, separate changes in reimbursement policies
52 have changed drug utilization and accessibility of the targeted therapies. Overall, removing
53 reimbursement restrictions and broadening eligible the patient population for NSCLC
54 targeted therapies improved the accessibility of such medications. In detail, when a targeted
55 therapy became available for either early or broad use, utilization increased, but this may
56
57
58
59
60

1
2
3
4 have in turn decreased the use of other drugs in a similar class. In addition, the targeted
5
6 therapies were prescribed faster once their insurance reimbursement restrictions were lifted.
7
8 The results of this study can be used as the empirical basis for clinical treatment, to help
9
10 enhance the content of academic literature on this subject, and can serve as the empirical
11
12 basis for future targeted therapy studies.
13
14

15 ■ Author Contributions

16 JCH and SCY conceptualized and designed the study. CFW collected data, performed
17
18 analysis, and drafted the manuscript. JCH and SCY reviewed all data and revised the
19
20 manuscript critically for intellectual content. All authors approved the final version for
21
22 submission.
23

24 ■ Competing Interests

25 The authors have no competing interests.
26
27

28 ■ Funding

29 Dr. Hsu was supported by Taiwan Ministry of Science and Technology grants (Grant ID:
30
31 MOST 104-2320-B-006-005, MOST 106-2320-B-006-039). The funders had no role in study
32
33 design, data collection and analysis, decision to publish, or preparation of the manuscript.
34

35 ■ Data Sharing Statement

36 The authors have obtained nationwide, monthly claims data for NSCLC patients, from 2004
37
38 to 2013, from the Taiwan National Health Insurance Research Database (NHIRD). NHIRD
39
40 does not permit external sharing of any of the data elements. No additional data available.
41
42
43
44

45 References

- 46 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide
47
48 burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893-917.
- 49 2. American Cancer Society: Cancer Facts & Figures 2012. Atlanta: American Cancer
50
51 Society. 2012.
- 52 3. Cancer Registry Annual Report, 2011, Taiwan. Health Promotion Administration,
53
54 Ministry of Health and Welfare 2014.
- 55 4. Pfizer Oncology, Lung cancer fact sheet. 2012.
- 56 5. Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential
57
58 role of cetuximab. *Biologics* 2009;3:215-24.
- 59 6. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer
60

1
2
3 therapy. *Expert Rev Anticancer Ther* 2007;7:1423-37.

4
5 7. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus
6 irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus
7 vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
8 *Ann Oncol* 2007;18:317-23.

9
10 8. Chen HL, Shen LJ, Wei CP, Lu HM, Hsiao FY. Decision to adopt medical technology
11 under the National Health Insurance System in Taiwan: case study of new molecular targeted
12 drugs among non-small cell lung cancer patients. *J Eval Clin Pract* 2015;21:808-16.

13
14 9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated
15 non-small-cell lung cancer. *N Engl J Med* 2005;353:123-32.

16
17 10. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of
18 non-small-cell lung cancer with erlotinib or gefitinib. *N Engl J Med* 2011;364:947-55.

19
20 11. NCCN Clinical Practice Guidelines in Oncology (2013) Non-Small Cell Lung Cancer, p.
21 2. National Comprehensive Cancer Network. Available at: <http://www.nccn.org/index.asp>
22 [accessed on Dec. 19,2015].

23
24 12. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for
25 non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380-8.

26
27 13. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. *Jpn J*
28 *Clin Oncol* 2009;39:137-50.

29
30 14. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary
31 adenocarcinoma. *N Engl J Med* 2009;361:947-57.

32
33 15. Sun JM, Lee KH, Kim SW, et al. Gefitinib versus pemetrexed as second-line treatment
34 in patients with nonsmall cell lung cancer previously treated with platinum-based
35 chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. *Cancer* 2012;118:6234-42.

36
37 16. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in
38 patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor
39 receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol*
40 2010;11:121-8.

41
42 17. Wu YL, Chu DT, Han B, et al. Phase III, randomized, open-label, first-line study in Asia
43 of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced
44 non-small-cell lung cancer: evaluation of patients recruited from mainland China. *Asia Pac J*
45 *Clin Oncol* 2012;8:232-43.

46
47 18. Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in
48 patients with advanced non-small cell lung cancer who failed previous chemotherapy. *Lung*
49 *Cancer* 2012;75:82-8.

50
51 19. Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study Comparing Gefitinib
52 With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG
53 5108L. *J Clin Oncol* 2016;34:3248-57.

54
55 20. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for
56 patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
57 CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*
58 2011;12:735-42.
59
60

21. Haspinger ER, Agustoni F, Torri V, et al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. *Crit Rev Oncol Hematol* 2015;94:213-27.
22. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. *Oncologist* 2015;20:400-10.
23. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. *Med Care* 2003;41:1331-42.
24. Analytic Hierarchy Process: Theory and Practice. 2009. (Accessed December 15, 2017, at ftp://mail.im.tku.edu.tw/Prof_Shyur/AHP/AHP2009.pdf).
25. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;27:299-309.
26. Lu CY, Ross-Degnan D, Stephens P, Liu B, Wagner AK. Changes in use of antidiabetic medications following price regulations in China (1999–2009). *Journal of Pharmaceutical Health Services Research* 2013;4:3-11.
27. Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. *BMJ* 2014;348:g3596.
28. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. *Health Policy* 2014;116:196-205.
29. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. *Med Care* 2010;48:4-9.
30. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. *BMJ* 2011;342:d108.
31. Shadish WC, T.; Campbell, D. *Experimental and Quasi-experimental Designs for Generalized Causal Inference* Houghton Mifflin 2002.
32. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. *J Clin Epidemiol* 2009;62:143-8.
33. Lewin J, Siu LL. Cancer genomics: the challenge of drug accessibility. *Curr Opin Oncol* 2015;27:250-7.
34. Morgan S, Kennedy J. Prescription drug accessibility and affordability in the United States and abroad. *Issue Brief (Commonw Fund)* 2010;89:1-12.
35. Davidoff AJ, Guy GP, Jr., Hu X, et al. Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History: Population-based National Estimates. *Med Care* 2018;56:220-7.
36. Saab S, Jimenez M, Fong T, et al. Accessibility to Oral Antiviral Therapy for Patients

1
2
3 with Chronic Hepatitis C in the United States. *J Clin Transl Hepatol* 2016;4:76-82.

4
5 37. Kuhlthau KA, Nipp RD, Shui A, et al. Health insurance coverage, care accessibility and
6 affordability for adult survivors of childhood cancer: a cross-sectional study of a nationally
7 representative database. *J Cancer Surviv* 2016;10:964-71.

8
9 38. Takayama A, Narukawa M. Comparison of New Drug Accessibility and Price Between
10 Japan and Major European Countries. *Ther Innov Regul Sci* 2017;51:604-11.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Prescription rate by patient number and market share by costs of targeted therapies over time (2004-2013)

	Prescription rate by patient number							Market share by costs						
	Number of patients who used antineoplastic agents	Number of patients who used gefitinib	(%)	Number of patients who used erlotinib	(%)	Number of patient who used targeted therapies (gefitinib + erlotinib)	(%)	Cost of antineoplastic agents (US\$)	Cost of gefitinib (US\$)	(%)	Cost of erlotinib (US\$)	(%)	Cost of Targeted therapies (gefitinib + erlotinib) (US\$)	(%)
2004	4,162	228	5.48	0	0.00	228	5.48	14,887,913	573,515	3.85	0	0.00	573,515	3.85
2005	4,876	872	17.88	0	0.00	872	17.88	22,446,991	8,015,889	35.71	0	0.00	8,015,889	35.71
2006	5,173	1095	21.17	0	0.00	1095	21.17	27,126,263	10,435,769	38.47	0	0.00	10,435,769	38.47
2007	5,909	1413	23.91	499	8.44	1912	32.36	29,531,282	12,265,156	41.53	2,694,918	9.13	14,960,074	50.66
2008	7,130	1975	27.70	1418	19.89	3393	47.59	43,162,957	18,784,869	43.52	11,190,711	25.93	29,975,581	69.45
2009	7,673	1922	25.05	2090	27.24	4012	52.29	48,988,605	17,276,102	35.27	18,099,806	36.95	35,375,908	72.21
2010	8,200	2058	25.10	2445	29.82	4503	54.91	51,384,668	16,242,224	31.61	20,207,860	39.33	36,450,084	70.94
2011	10,254	3440	33.55	2754	26.86	6194	60.41	58,115,193	20,942,858	36.04	19,298,723	33.21	40,241,581	69.24
2012	12,621	5011	39.70	3029	24.00	8040	63.70	76,127,283	36,628,520	48.11	17,785,455	23.36	54,413,975	71.48
2013	14,597	5558	38.08	2984	20.44	8542	58.52	91,642,044	41,677,315	45.48	15,488,583	16.90	57,165,899	62.38

Table 2. Estimated changes in targeted therapies utilization following changes in reimbursement policies using segmented regression models

	Intercept	Effects of intervention (1) erlotinib covered by NHI (third line) [200706]				Effects of intervention (2) gefitinib became second line treatment [200711]			Effects of intervention (3) erlotinib became second line treatment [200806]			Effects of intervention (4) gefitinib became first line treatment [201106]		
		Baseline trend	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)	Level change	Trend change	Relative change (3 months later)
Prescribing rate of targeted therapies	0.0342	0.0041 (0.0021, 0.0060)	NS	NS	NS	NS	0.0121 (0.0027, 0.0215)	15.58%	NS	-0.0140 (-0.0226, -0.0054)	-10.98%	0.0264 (0.0037, 0.0491)	NS	6.31%
Prescribing rate of gefitinib	0.0263	0.0042 (0.0017, 0.0067)	NS	-0.0146 (-0.0268, -0.0024)	-20.69%	NS	0.0210 (0.0048, 0.0372)	54.32%	NS	-0.0112 (-0.0211, -0.0013)	-13.27%	0.0215 (0.0026, 0.0404)	0.0072 (0.0032, 0.0113)	21.76%
Prescribing rate of erlotinib	0.0099	0.0127 (0.0059, 0.0195)	NA	NA	NA	NS	-0.0100 (-0.0173, -0.0026)	-26.79%	0.0228 (0.0060, 0.0396)	NS	22.62%	NS	-0.0076 (-0.0105, -0.0048)	-10.30%
Market share by cost for targeted therapies	0.0446	0.0068 (0.0045, 0.0091)	NS	NS	0	NS	NS	0	NS	-0.0062 (-0.0095, -0.0028)	-4.33%	NS	NS	0
Market share by cost for gefitinib	0.1030	0.0043 (0.0014, 0.0067)	NS	-0.0064 (-0.0106, -0.0022)	-6.59%	NS	NS	0	NS	NS	0	NS	0.0095 (0.0052, 0.0138)	16.63%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

0.0072) -0.0023) 0.0137)

		0.0202						-0.0183	0.0302				-0.0074
Market share by cost for erlotinib	0.0194	(0.0113, 0.0291)	NA	NA	NA	NS	(-0.0278, -0.0088)	-30.33%	(0.0077, 0.0527)	NS	21.66%	NS	(-0.0108, -0.0040)

The relative changes = (actual value-predicted value) in outcomes 3 months following the interventions / predicted value in outcomes 3 months following the interventions
 NS = not significant; NA=not available

For peer review only

Table 3. Time to prescription of targeted therapies for non-small cell lung cancer treatment over time (2004-2013)

	Time to Prescription (days)					
	Targeted therapies (gefitinib + erlotinib)		Gefitinib		Erlotinib	
	Mean	S.D.	Mean	S.D.	Mean	S.D.
2004	801.7	654.6	685.3	587.4	1,602.0	520.7
2005	683.4	546.2	570.0	497.4	1,128.7	500.4
2006	603.0	471.2	522.1	440.9	743.2	489.4
2007	457.6	397.7	402.4	394.6	524.2	391.4
2008	383.0	343.7	390.1	379.9	377.6	313.1
2009	369.3	315.7	382.1	340.7	359.2	294.2
2010	329.8	242.9	325.6	247.7	333.4	238.8
2011	207.2	207.0	137.9	182.4	313.5	197.2
2012	120.3	137.4	68.5	104.3	249.1	124.7
2013	43.0	49.6	32.5	33.7	128.9	70.8

Table 4. Estimated changes in average time to prescription for NSCLC targeted therapies following changes in reimbursement policies

	Impact of erlotinib covered by NHI and gefitinib/erlotinib as second line treatments in 2007 and 2008			Impact of gefitinib as first line treatment in 2011				
	Intercept	Baseline trend	Level change	Trend change	Relative change (2 year later)	Level change	Trend change	Relative change (2 year later)
Average Time to Prescription (days)								
Targeted Therapies (gefitinib+erlotinib)	922.5246	-116.0248 (-131.6088, -100.4408)	NS	67.9176 (41.1362, 94.6990)	-65.84% (-68.30%, -63.37%)	NS	-45.3087 (-72.0901, -18.5273)	-41.59% (-57.24%, -25.93%)
gefitinib	759.1598	-83.6959 (-100.3257, -67.0661)	NS	51.1611 (23.5177, 78.8045)	39.82% (9.87%, 69.77%)	-182.0687 (-245.2401, -118.8973)	NS	-69.57% (-81.08%, -58.07%)
erlotinib	1905.0000	-362.5991 (-404.6915, -320.5067)	NS	316.5921 (260.7650, 372.4192)	-234.37% (-318.17%, -150.57%)	NS	NS	0.00%

The relative changes = (actual value-predicted value) in outcomes 2 years following the interventions / predicted value in outcomes 2 years following the interventions

NS = not significant; NA=not available

Figure Legends

Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib.

Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

For peer review only




Figure 1. Prescribing rate by patient number of targeted therapies over time: (A) targeted therapies (gefitinib + erlotinib), (B) gefitinib, (C) erlotinib. Prescription rate of targeted therapies by patient number = number of patients who used targeted therapies / number of patients who used antineoplastic agents

134x272mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

Page		Item No	Recommendation
1-2	Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
1-2			(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction			
3-4	Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
4	Objectives	3	State specific objectives, including any prespecified hypotheses
Methods			
4-5	Study design	4	Present key elements of study design early in the paper
4-5	Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
4-5	Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
NA			(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
5	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
4-5	Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
5-7	Bias	9	Describe any efforts to address potential sources of bias
7	Study size	10	Explain how the study size was arrived at
5-7	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
5-7	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
5-7			(b) Describe any methods used to examine subgroups and interactions
5-7			(c) Explain how missing data were addressed
5-7			(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
NA			(e) Describe any sensitivity analyses

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

7	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
5			(b) Give reasons for non-participation at each stage
NA			(c) Consider use of a flow diagram
7-9	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
7			(b) Indicate number of participants with missing data for each variable of interest
7-9			(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
NA	Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time
NA			<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure
9-10			<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
7-10	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
NA			(b) Report category boundaries when continuous variables were categorized
NA			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
NA	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

10-12	Key results	18	Summarise key results with reference to study objectives
12	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
10-12	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
10-13	Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

13	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
----	---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.